Document:

Exhibit
10.1

 

SECURITIES
PURCHASE AGREEMENT

 

This
Securities Purchase Agreement (this “Agreement”)
is dated as of October 21, 2016, by and among Cachet Financial Solutions, Inc., a Delaware corporation (the “Company”),
the parties indicated as Purchasers on Schedule I attached hereto and on one or more counterpart signature pages hereof,
and the parties that may become parties to this Agreement in accordance with Section 5.1 of this Agreement (each of the parties
indicated as Purchasers on Schedule I attached hereto and on one or more counterpart signature pages hereof and the parties
that may become parties to this Agreement in accordance with Section 5.1 of this Agreement is a “Purchaser,”
and collectively the “Purchasers”).

 

WHEREAS,
subject to the terms and conditions set forth in this Agreement and pursuant to an exemption from the registration requirements
of Section 5 of the Securities Act, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and
not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement;

 

NOW,
THEREFORE, in consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration
the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser hereby agree as follows:

 

ARTICLE
I.

DEFINITIONS

 

1.1
Definitions. In addition to the terms defined elsewhere in this Agreement, (a) capitalized terms that are not otherwise
defined herein have the meanings given to such terms in the Warrant (as defined herein), and (b) the following terms have the
meanings set forth in this Section 1.1:

 

“Action”
shall have the meaning ascribed to such term in Section 3.1(j).

 

“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person as such terms are used in and construed under Rule 405 under the Securities Act.

 

“Board
of Directors” means the Board of Directors of the Company.

 

“Business
Day” means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or
any day on which banking institutions in the State of New York are authorized or required by law or other governmental action
to close.

 

“Closing”
means, with respect to any Purchaser, the closing of the purchase and sale of the Securities to such Purchaser pursuant to Section
2.1.

 

“Closing
Date” means, as to any Purchaser, the Trading Day on which all of the Transaction Documents have been executed and delivered
by the Company and such Purchaser, and all conditions precedent to (i) such Purchaser’s obligation to pay the Subscription
Amount payable by such Purchaser as set forth on Schedule I attached hereto and (ii) the Company’s obligation to
deliver the Securities purchased by such Purchaser, in each case, have been satisfied or waived, but in no event later than the
third Trading Day following the date on which such Purchaser has executed a counterpart hereof.

 

    	 	 	 

    	 	 	 

    

 

“Commission”
means the United States Securities and Exchange Commission.

 

“Common
Stock” means the common stock of the Company, par value $0.0001 per share, and any other class of securities into which
such securities may hereafter be reclassified or changed.

 

“Common
Stock Equivalents” means any securities of the Company or the Subsidiaries which would entitle the holder thereof to
acquire at any time Common Stock.

 

“Conversion
Price” shall have the meaning ascribed to such term in the applicable Convertible Note.

 

“Conversion
Shares” shall have the meaning ascribed to such term in the applicable Convertible Note.

 

“Convertible
Note” means the Convertible Term Promissory Note in the form attached hereto as Exhibit A, convertible into shares
of Common Stock at the Conversion Price (subject to adjustment as provided therein).

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder.

 

“GAAP”
shall have the meaning ascribed to such term in Section 3.1(h).

 

“Intellectual
Property Rights” shall have the meaning ascribed to such term in Section 3.1(m).

 

“Lien”
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.

 

“Material
Adverse Effect” shall have the meaning assigned to such term in Section 3.1(b).

 

“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

 

“Proceeding”
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial
proceeding, such as a deposition), whether commenced or threatened.

 

“Purchaser
Party” shall have the meaning ascribed to such term in Section 4.8.

 

“Required
Approvals” shall have the meaning ascribed to such term in Section 3.1(e).

 

“Resale
Registration Statement” shall have the meaning ascribed to such term in Section 4.4.

 

    	 	2	 

     

    

 

“Rule
144” means Rule 144, promulgated by the Commission pursuant to the Securities Act, as such Rule 144 may be amended or
interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the
same purpose and effect as such Rule.

 

“SEC
Reports” shall have the meaning ascribed to such term in Section 3.1(h).

 

“Securities”
means the Convertible Notes and the Warrants.

 

“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations thereunder.

 

“Senior
Obligations” means, collectively, all secured indebtedness of the Company in an aggregate amount of up to $1,500,000
that may be incurred at any time after the date hereof under any credit facility with, borrowed from or otherwise becoming owed
by agreement to an “institutional lender” (as defined below), which credit facility or other agreement provides the
Company with revolving credit loans, term loans, letters of credit or other working capital availability, including all principal,
interest (including interest accruing on or after the filing of petition in bankruptcy or for reorganization relating to the Company),
fees, charges, expenses and all other amounts payable thereunder or in respect thereof and together with any refinancing, extensions,
amendments, modifications, restructurings, renewals or replacements of any of the foregoing. As used above, “institutional
lender” means and includes a federally chartered ‘national bank’ or ‘national association,’ a state
chartered ‘insurance company’ or mutual insurance company, or state chartered bank, an investment banking entity or
institution, or any other Person that is (or will be) engaged in making, purchasing, holding or otherwise investing in commercial
loans and similar extensions of credit in the ordinary course of its activities.

 

“Shares”
means the shares of Common Stock issuable to each Purchaser pursuant to this Agreement.

 

“Short
Sales” means all “short sales” as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall
not be deemed to include the location and/or reservation of borrowable shares of Common Stock).

 

“Subscription
Amount” means, as to each Purchaser, the aggregate amount to be paid for the Convertible Notes and the Warrants purchased
by such Purchaser hereunder as set forth opposite such Purchaser’s name under the column entitled “Subscription
Amount” on Schedule I attached hereto, in United States dollars and in immediately available funds.

 

“Subsidiary”
means Cachet Financial Solutions Inc., a Minnesota corporation.

 

“Trading
Day” means a day on which the principal Trading Market is open for trading.

 

“Trading
Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on
the date in question: the NYSE MKT, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the
New York Stock Exchange, the OTC Bulletin Board or the OTC Markets (e.g., OTCQX or OTCQB), or any successors to any of the foregoing.

 

    	 	3	 

     

    

 

“Transaction
Documents” means this Agreement, the Convertible Notes, the Warrants, all exhibits and schedules thereto and any other
documents or agreements executed in connection with the transactions contemplated hereunder.

 

“Underlying
Shares” means the Conversion Shares and the Warrant Shares.

 

“Warrant”
means the Warrant to Purchase Common Stock in the form of Exhibit B attached hereto.

 

“Warrant
Shares” means the shares of Common Stock issuable upon exercise of a Warrant.

 

ARTICLE
II.

PURCHASE AND SALE

 

2.1Closing.
At the Closing, upon the terms and subject to the conditions set forth herein, substantially concurrent with the execution and
delivery of this Agreement by the parties hereto, the Company agrees to sell to each Purchaser acquiring Securities hereunder
at such Closing, and such Purchaser agrees to purchase from the Company, (a) a Convertible Note with such principal amount as
set forth opposite such Purchaser’s name under the column entitled “Note Principal Amount” on Schedule
I attached hereto for a purchase price equal to such Purchaser’s Subscription Amount, and (b) a Warrant to purchase
up to such number of shares of Common Stock as set forth opposite such Purchaser’s name under the column entitled “Number
of Warrants” on Schedule I attached hereto, subject to adjustment as provided therein. At the Closing, (i) each
Purchaser acquiring Securities hereunder at such Closing shall deliver to the Company, via wire transfer of immediately available
funds, such Purchaser’s Subscription Amount, (ii) the Company shall deliver to such Purchaser such Purchaser’s Convertible
Note and Warrant, and (iii) the Company and such Purchaser shall deliver the other items set forth in Section 2.2.

 

2.2Deliveries.

 

(a)At
the Closing, the Company shall deliver or cause to be delivered to each Purchaser acquiring Securities hereunder at such Closing
the following:

 

(i)this
Agreement duly executed by the Company;

 

(ii)a
Convertible Note, registered in such name or names as such Purchaser shall specify to the Company in writing, in the principal
amount set forth opposite such Purchaser’s name under the column entitled “Note Principal Amount” on
Schedule I attached hereto; and

 

(iii)a
Warrant registered in the name of such Purchaser to purchase up to the number of shares of Common Stock set forth opposite such
Purchaser’s name under the column entitled “Number of Warrants” on Schedule I attached hereto.

 

(b)At
the Closing, each Purchaser acquiring Securities hereunder at such Closing shall deliver or cause to be delivered to the Company
the following:

 

(i)this
Agreement duly executed by such Purchaser; and

 

    	 	4	 

     

    

 

(ii)such
Purchaser’s Subscription Amount by wire transfer to the account specified in writing by the Company.

 

2.3Closing
Conditions.

 

(a)The
obligations of the Company hereunder in connection with any Closing are subject to the following conditions being met:

 

(i)all
representations and warranties of the Purchaser acquiring Securities hereunder at such Closing contained herein shall have been
accurate in all material respects when made and on the Closing Date (unless as of a specific date therein in which case they shall
have been accurate as of such date);

 

(ii)all
obligations, covenants and agreements of the Purchaser acquiring Securities hereunder at such Closing required to be performed
at or prior to the Closing Date shall have been performed; and

 

(iii)there
shall have been no Material Adverse Effect with respect to the Company since the date hereof.

 

(iv)the
Company shall have obtained all necessary “blue sky” law permits and qualifications, or have the availability of exemptions
therefrom, required by any state for the offer and sale of the Securities and issuance of the Underlying Shares; and

 

(v)the
Purchaser acquiring Securities hereunder at such Closing shall have delivered all of the items set forth in Section 2.2(b) of
this Agreement.

 

(b)The
respective obligations of each Purchaser hereunder in connection with the Closing in which such Purchaser participates are subject
to the following conditions being met:

 

(i)all
representations and warranties of the Company contained herein shall have been accurate in all material respects when made and
on the applicable Closing Date (unless as of a specific date therein in which case they shall have been accurate as of such date);

 

(ii)all
obligations, covenants and agreements of the Company required to be performed at or prior to the applicable Closing Date shall
have been performed;

 

(iii)the
Company shall have delivered all of the items set forth in Section 2.2(a) of this Agreement; and

 

(iv)there
shall have been no Material Adverse Effect with respect to the Company since the date hereof.

 

    	 	5	 

     

    

 

ARTICLE
III.

REPRESENTATIONS AND WARRANTIES

 

3.1Representations
and Warranties of the Company. Except as set forth in the Company’s SEC Reports, which shall qualify any representation
or warranty otherwise made herein to the extent of the disclosure contained in the corresponding section of the SEC Reports, the
Company hereby makes the following representations and warranties to each Purchaser:

 

(a)Subsidiaries.
All of the direct and indirect subsidiaries of the Company are set forth in the Company’s SEC Reports. The Company owns,
directly or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens except
for Liens in connection with financing arrangements disclosed in the SEC Reports, and all of the issued and outstanding shares
of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar rights
to subscribe for or purchase securities.

 

(b)Organization
and Qualification. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly
existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power
and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company
nor any Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles of incorporation,
bylaws or other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business
and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted
or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as
the case may be, would not reasonably be expected to result in: (i) a material adverse effect on the legality, validity or enforceability
of any Transaction Document, (ii) a material adverse effect on the results of operations, assets, business or condition (financial
or otherwise) of the Company and the Subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company’s
ability to perform in any material respect on a timely basis its obligations under any Transaction Document (any of (i), (ii)
or (iii), a “Material Adverse Effect”).

 

(c)Authorization;
Enforcement. The Company has the requisite corporate power and authority to enter into and to consummate the transactions
contemplated by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder
and thereunder. The execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the
consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the
part of the Company and no further action is required by the Company, the Board of Directors or the Company’s stockholders
in connection herewith or therewith other than in connection with the Required Approvals. This Agreement and each other Transaction
Document to which it is a party has been (or upon delivery will have been) duly executed by the Company and, when delivered in
accordance with the terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against
the Company in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency,
reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (ii)
as limited by laws relating to the availability of injunctive relief or other equitable remedies and (iii) insofar as indemnification
and contribution provisions may be limited by applicable law.

 

    	 	6	 

     

    

 

(d)No
Conflicts. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to
which it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby
and thereby do not and will not (i) conflict with or violate any provision of the Company’s or any Subsidiary’s certificate
or articles of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default
(or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon
any of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, acceleration
or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing
a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by which
any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict
with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court
or governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations),
or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii)
and (iii), such as would not reasonably be expected to result in a Material Adverse Effect.

 

(e)Filings,
Consents and Approvals. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice
to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other
Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i)
any filings with the Commission pursuant to Sections 4.1 and 4.2, and (ii) the notice and/or application(s) to each applicable
Trading Market for the issuance and sale of the Securities and the listing of the Underlying Shares for trading thereon in the
time and manner required thereby, if any (collectively, the “Required Approvals”).

 

(f)Issuance
of the Securities. The Shares are duly authorized and, when issued and paid for in accordance with the applicable Transaction
Documents, will be duly and validly issued, fully paid and non-assessable, free and clear of all Liens imposed by the Company
other than restrictions on transfer provided for in the Transaction Documents and under applicable state and federal securities
laws. The Underlying Shares, when issued in accordance with the terms of the Transaction Documents, will be validly issued, fully
paid and non-assessable, free and clear of all Liens imposed by the Company other than restrictions on transfer provided for in
the Transaction Documents. The Underlying Shares have been duly reserved for issuance upon exercise of the Warrants.

 

    	 	7	 

     

    

 

(g)Capitalization.
The issued and outstanding shares of Common Stock have been duly authorized and validly issued, are fully paid and nonassessable,
have been issued in compliance with all federal and state securities laws, were not issued in violation of or subject to any preemptive
rights or other rights to subscribe for or purchase securities, and conform in all material respects to the description thereof
contained in the Company’s filings with the SEC. The Company has not issued any capital stock except as may be disclosed
in SEC Reports, other than pursuant to the exercise of employee stock options under the Company’s stock option plans, the
issuance of shares of Common Stock to employees pursuant to the Company’s employee stock purchase plans and pursuant to
the conversion and/or exercise of Common Stock Equivalents disclosed in SEC Reports. No Person has any right of first refusal,
preemptive right, right of participation, or any similar right to participate in the transactions contemplated by the Transaction
Documents. Except as a result of the purchase and sale of the Securities, and except as disclosed in the SEC Reports, there are
no outstanding options, warrants, rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities,
rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or
acquire, any shares of Common Stock, or contracts, commitments, understandings or arrangements by which the Company or any Subsidiary
is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents. Except as disclosed in the Company’s
SEC Reports, the issuance and sale of the Securities will not obligate the Company to issue shares of Common Stock or other securities
to any Person (other than the Purchasers) and will not result in a right of any holder of Company securities to adjust the exercise,
conversion, exchange or reset price under any of such securities.

 

(h)SEC
Reports; Financial Statements. The Company has filed all reports, schedules, forms, statements and other documents required
to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof,
for the two (2) years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file
such material) including the Company’s Registration Statement on Form S-1 (File No. 333-212610) initially filed with the
Commission on July 20, 2016 (which has not been declared effective by the Commission and the Company has applied for withdrawal
of such registration statement on October 19, 2016) (the foregoing materials, including the exhibits thereto and documents incorporated
by reference therein, being collectively referred to herein as the “SEC Reports”). As of their respective dates, the
SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable,
and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact
required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which
they were made, not misleading. The financial statements of the Company included in the SEC Reports comply in all material respects
with applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at the
time of filing. Such financial statements have been prepared in accordance with United States generally accepted accounting principles
applied on a consistent basis during the periods involved (“GAAP”), except as may be otherwise specified in such financial
statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP,
and fairly present in all material respects the financial position of the Company and its consolidated Subsidiaries as of and
for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited
statements, to normal, immaterial, year-end audit adjustments.

 

(i)Material
Changes; Undisclosed Events, Liabilities or Developments. Since the date of the latest audited financial statements included
within the SEC Reports, except as specifically disclosed in a subsequent SEC Report filed prior to the date hereof, (i) there
has been no event, occurrence or development that has had or that could reasonably be expected to result in a Material Adverse
Effect, (ii) the Company has not incurred any material liabilities (contingent or otherwise) other than (A) trade payables and
accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities not required to
be reflected in the Company’s financial statements pursuant to GAAP or disclosed in filings made with the Commission, (iii)
the Company has not altered its method of accounting, and (iv) the Company has not declared or made any dividend or distribution
of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of
its capital stock. Except as disclosed in the Company’s Current Report on Form 8-K filed on July 15, 2016, the Company does
not have pending before the Commission any request for confidential treatment of information.

 

    	 	8	 

     

    

 

(j)Litigation.
Except as disclosed in the Company’s SEC Reports, there is no action, suit, inquiry, notice of violation, proceeding or
investigation pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any
of their respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority
(federal, state, county, local or foreign) (collectively, an “Action”) which (i) adversely affects or challenges
the legality, validity or enforceability of any of the Transaction Documents or the Securities or (ii) could, if there were an
unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. The Commission has not issued any
stop order or other order suspending the effectiveness of any registration statement filed by the Company or any Subsidiary under
the Exchange Act or the Securities Act. 

 

(k)Compliance.
Except as disclosed in the Company’s SEC Reports, neither the Company nor any Subsidiary: (i) is in default under or in
violation of (and no event has occurred that has not been waived that, with notice or lapse of time or both, would result in a
default by the Company or any Subsidiary under), nor has the Company or any Subsidiary received notice of a claim that it is in
default under or that it is in violation of, any indenture, loan or credit agreement or any other agreement or instrument to which
it is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived), (ii)
is in violation of any judgment, decree or order of any court, arbitrator or other governmental authority or (iii) is or has been
in violation of any statute, rule, ordinance or regulation of any governmental authority, including without limitation all foreign,
federal, state and local laws relating to taxes, environmental protection, occupational health and safety, product quality and
safety and employment and labor matters, except in each case described in clauses (i) – (iii) above as would not reasonably
be expected to result in a Material Adverse Effect.

 

(l)Title
to Assets. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them
and good and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries,
in each case free and clear of all Liens, except for (i) Liens as do not materially interfere with the use made and proposed to
be made of such property by the Company and the Subsidiaries, (ii) Liens for the payment of federal, state or other taxes, for
which appropriate reserves have been made in accordance with GAAP and, the payment of which is neither delinquent nor subject
to penalties and (iii) Liens in connection with financing arrangements disclosed in the SEC Reports.

 

    	 	9	 

     

    

 

(m)Intellectual
Property. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark
applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights
and similar rights necessary or required for use in connection with their respective businesses as described in the SEC Reports
and which the failure to so have could have a Material Adverse Effect (collectively, the “Intellectual Property Rights”).
None of, and neither the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual
Property Rights has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two years
from the date of this Agreement. Neither the Company nor any Subsidiary has received, since the date of the latest audited financial
statements included within the SEC Reports, a written notice of a claim or otherwise has any knowledge that the Intellectual Property
Rights violate or infringe upon the rights of any Person, except as would not reasonably be expected to not have a Material Adverse
Effect or except as disclosed in the SEC Reports. To the knowledge of the Company, all such Intellectual Property Rights are enforceable
and there is no existing infringement by another Person of any of the Intellectual Property Rights. The Company and its Subsidiaries
have taken reasonable security measures to protect the secrecy, confidentiality and value of all of their intellectual properties,
except where failure to do so could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

 

(n)[Reserved.]

 

(o)Tax
Status. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a
Material Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local
income and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is
subject, (ii) has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined
to be due on such returns, reports and declarations and (iii) has set aside on its books provision reasonably adequate for the
payment of all material taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There
are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of
the Company or of any Subsidiary know of no basis for any such claim.

 

(p)Investment
Company. The Company (including its subsidiaries) is not an “investment company” or an “affiliated person”
of, or “promoter” or “principal underwriter” for an investment company, within the meaning of the Investment
Company Act of 1940 and will not be deemed an “investment company” as a result of the transactions contemplated by
this Agreement.

 

(q)Related
Party Transactions. To the knowledge of the Company, no material transaction has occurred between or among the Company and
any of its affiliates (including, without limitation, any of its subsidiaries), officers or directors or any affiliate or affiliates
of any such affiliate, officer or director that with the passage of time will be required to be disclosed pursuant to Sections
13, 14 or 15(d) of the Exchange Act, other than (1) those transactions that have already been so disclosed, or will be so disclosed
on or before the Closing Date, in the Company’s SEC Reports.

 

(r)No
General Solicitation. Neither the Company, nor any of its affiliates, nor any person action on its or their behalf, has engaged
in any form of general solicitation or general advertising (within the meaning of Regulation D promulgated under the Securities
Act) in connection with the offer or sale of the Securities.

 

    	 	10	 

     

    

 

(s)No
Manipulation; Disclosure of Information. The Company has not taken and will not take any action designed to or that might
reasonably be expected to cause or result in an unlawful manipulation of the price of the Common Stock to facilitate the sale
or resale of the Securities. The Company confirms that, to its knowledge, with the exception of the proposed sale of Securities
as contemplated herein (as to which the Company makes no representation), neither it nor any other person acting on its behalf
has provided any of the Purchasers or their agents or counsel with any information that constitutes or might constitute material,
non-public information. The Company understands and confirms that the Purchasers will be relying on the foregoing representations
in effecting transactions in securities of the Company. All disclosures provided to the Purchasers regarding the Company, its
business and the transactions contemplated hereby furnished by the Company are true and correct and do not contain any untrue
statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in light
of the circumstances under which they were made, not misleading.

 

(t)Forward-Looking
Statements. No forward-looking statement (within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange
Act) made by the Company or any of its officers or directors contained in the SEC Reports, or made available to the public generally
since December 31, 2015, has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith.

 

(u)No
Additional Agreements. Other than with respect to closing mechanics, the Company has no other agreements or understandings
(including, without limitation, side letters) with any Purchaser or other person to purchase any of the Securities on terms more
favorable to such person than as set forth herein.

 

(v)No
“Bad Actor” Disqualification. The Company has exercised reasonable care, in accordance with SEC rules and guidance,
and has conducted a factual inquiry, the nature and scope of which reflect reasonable care under the relevant facts and circumstances,
to determine whether any Covered Person (as defined below) is subject to any of the “bad actor” disqualifications
described in Rule 506(d)(1)(i) to (viii) under the Securities Act (“Disqualification Events”). To the Company’s
knowledge, after conducting such sufficiently diligent factual inquiries, no Covered Person is subject to a Disqualification Event,
except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3) under the Securities Act. The Company has complied, to
the extent applicable, with any disclosure obligations under Rule 506(e) under the Securities Act. “Covered Persons”
are those persons specified in Rule 506(d)(1) under the Securities Act, including the Company; any predecessor or affiliate of
the Company; any director, executive officer, other officer participating in the offering, general partner or managing member
of the Company; any beneficial owner of 20% or more of the Company’s outstanding voting equity securities, calculated on
the basis of voting power; any promoter (as defined in Rule 405 under the Securities Act) connected with the Company in any capacity
at the time of the sale of the Convertible Notes; and any person that has been or will be paid (directly or indirectly) remuneration
for solicitation of purchasers in connection with the sale of the Convertible Notes (a “Solicitor”), any general partner
or managing member of any Solicitor, and any director, executive officer or other officer participating in the offering of any
Solicitor or general partner or managing member of any Solicitor.

 

    	 	11	 

     

    

 

Each
Purchaser, for itself and for no other Purchaser, acknowledges and agrees that the representations contained in Section 3.1 shall
not modify, amend or affect the Company’s right to rely on such Purchaser’s representations and warranties contained
in this Agreement or any representations and warranties contained in any other Transaction Document or any other document or instrument
executed or delivered in connection with this Agreement or the consummation of the transactions contemplated hereby.

 

3.2Representations
and Warranties of the Purchasers. Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants as
of the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein):

 

(a)Organization;
Authority. Such Purchaser is either an individual or an entity duly incorporation or formation, validly existing and in good
standing under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited
liability company or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction
Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents
and performance by such Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all
necessary corporate, partnership, limited liability company or similar action, as applicable, on the part of such Purchaser. Each
Transaction Document to which it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser in
accordance with the terms hereof, will constitute the valid and legally binding obligation of such Purchaser, enforceable against
it in accordance with its terms, except: (i) as limited by general equitable principles and applicable bankruptcy, insolvency,
reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (ii)
as limited by laws relating to the availability of injunctive relief or other equitable remedies and (iii) insofar as indemnification
and contribution provisions may be limited by applicable law.

 

(b)Understandings
or Arrangements. Such Purchaser is acquiring the Securities as principal for its own account and has no direct or indirect
arrangement or understandings with any other persons to distribute or regarding the distribution of the Securities (this representation
and warranty not limiting such Purchaser’s right to sell the Securities pursuant to the Resale Registration Statement or
otherwise in compliance with applicable federal and state securities laws). Such Purchaser is acquiring the Securities hereunder
in the ordinary course of its business. Such Purchaser understands that (i) on October 19, 2016, the
Company has applied for withdrawal of the Company’s Registration Statement on Form S-1 (File No. 333-212610) initially filed
with the Commission on July 20, 2016 (which registration statement has not been declared effective by the Commission),
(ii) the offering of Securities to the Purchasers hereunder is not registered under the Securities Act and the Purchasers of Securities
hereunder do not have the protection of Section 11 of the Securities Act, (iii) the Convertible Notes, Warrants and Underlying
Shares have not been registered under the Securities Act or any applicable state securities law and are and will be “restricted
securities” (as that term is defined in Rule 144(a)(3) under the Securities Act) and may not be resold unless they are
registered under the Securities Act or an exemption from registration is available and (iv) such Purchaser is acquiring the
Securities as principal for its own account and not with a view to or for distributing or reselling the Securities or any part
thereof in violation of the Securities Act or any applicable state securities law, has no present intention of distributing any
of the Securities in violation of the Securities Act or any applicable state securities law and has no direct or indirect arrangement
or understandings with any other persons to distribute or regarding the distribution of the Securities in violation of the Securities
Act or any applicable state securities law (this representation and warranty not limiting such Purchaser’s right to sell
the Securities pursuant to the Resale Registration Statement or otherwise in compliance with applicable federal and state securities
laws). The Purchaser is acquiring the Securities hereunder in the ordinary course of its business.

 

    	 	12	 

     

    

 

(c)Opportunity
to Obtain Information. Such Purchaser acknowledges that representatives of the Company have made available to such Purchaser
the opportunity to review the books and records of the Company and its Subsidiaries and to ask questions of and receive answers
from such representatives concerning the business and affairs of the Company and its Subsidiaries. Such Purchaser further acknowledges
the availability of the Company’s SEC Reports, specifically include the Company’s Annual Report on Form 10-K for the
year ended December 31, 2015.

 

(d)Purchaser
Status. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is and at the Closing
will be, and on each date on which it converts any portion of a Convertible Note or exercises any Warrants, it will be an “accredited
investor” as defined in Rule 501 under the Securities Act.

 

(e)Experience
of Such Purchaser. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication and
experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment
in the Securities, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk
of an investment in the Securities and, at the present time, is able to afford a complete loss of such investment.

 

(f)General
Solicitation. Such Purchaser is not purchasing the Securities as a result of any advertisement, article, notice or other communication
regarding the Securities or any other securities of the Company published in any newspaper, magazine or similar media or broadcast
over television or radio or presented at any seminar or any other general solicitation or general advertisement. Such Purchaser
has a pre-existing relationship with the Company.

 

(g)No
Investment, Tax or Legal Advice. Each Purchaser understands that nothing in the Company SEC Reports, this Agreement, or any
other materials presented to the Purchaser in connection with the purchase and sale of the Securities constitutes legal, tax or
investment advice. Each Purchaser has consulted such legal, tax and investment advisors as it, in its sole discretion, has deemed
necessary or appropriate in connection with its purchase of Securities.

 

    	 	13	 

     

    

 

(h)Certain
Transactions and Confidentiality. Other than consummating the transactions contemplated hereunder, such Purchaser has not,
nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any
purchases or sales, including Short Sales, of the securities of the Company during the period commencing as of the time that such
Purchaser first received a term sheet (written or oral) from the Company or any other Person representing the Company setting
forth the material terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding
the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage
separate portions of such Purchaser’s assets and the portfolio managers have no knowledge of the investment decisions made
by the portfolio managers managing other portions of such Purchaser’s assets, the representation set forth above shall only
apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the
Securities covered by this Agreement. Other than to other Persons party to this Agreement, such Purchaser has maintained the confidentiality
of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction). 

 

The
Company acknowledges and agrees that the representations contained in Section 3.2 shall not modify, amend or affect such Purchaser’s
right to rely on the Company’s representations and warranties contained in this Agreement or any representations and warranties
contained in any other Transaction Document or any other document or instrument executed and/or delivered in connection with this
Agreement or the consummation of the transaction contemplated hereby.

 

ARTICLE
IV.

OTHER AGREEMENTS OF THE PARTIES

 

4.1Reporting
Status. With a view to making available to the Purchasers the benefits of certain rules and regulations of the SEC which may
permit the sale of the Shares and Underlying Shares to the public without registration, the Company agrees to use its reasonable
efforts to file with the SEC, in a timely manner, all reports and other documents required of the Company under the Exchange Act.
The Company will otherwise take such further action as a Purchaser may reasonably request, all to the extent required from time
to time to enable such Purchaser to sell the Securities and Underlying Shares without registration under the Securities Act or
any successor rule or regulation adopted by the SEC.

 

4.2Quotation.
So long as a Purchaser owns any of the Securities or Underlying Shares, the Company will use its reasonable efforts to maintain
the quotation of its Common Stock on the OTCQB or OTCQX, each as administered by OTC Markets Group or, in lieu thereof, on a national
securities exchange and will comply in all material respects with the Company’s reporting, filing and other obligations
under the rules of any such market or exchange, as applicable.

 

4.3Non-Public
Information. The Company covenants and agrees that neither it nor any other person acting on its behalf will provide any Purchaser
or its agents or counsel with any information that the Company believes constitutes material non-public information, unless prior
thereto such Purchaser shall have executed a written agreement regarding the confidentiality and use of such information. The
Company understands and confirms that each Purchaser shall be relying on the foregoing representations in effecting transactions
in securities of the Company. Furthermore, if the Company has disclosed any material non-public information to the Purchaser,
the Purchaser has no duty to keep such information confidential following the public announcement of the offering.

 

4.4Resale
Registration Statement. Within 21 days following the Company’s next underwritten public offering or 90 days following
the date that the Company’s current financing plan is terminated (the “Resale Date”) the Company shall
file, and thereafter use its reasonable best efforts to effect the registration, qualification and compliance (including without
limitation the execution of an undertaking to file post-effective amendments, appropriate qualification under applicable blue
sky or other state securities laws and appropriate compliance with applicable regulations issued under the Securities Act and
any other governmental requirements or regulations) to permit or facilitate the sale and distribution of all of the Common Stock
and Underlying Shares no later than ninety (90) days after the Resale Date (such registration statement, the “Resale
Registration Statement”); provided, however, that the Company shall not be obligated to take any action to effect any
such registration, qualification or compliance:

 

    	 	14	 

     

    

 

(a)in
any particular jurisdiction in which the Company would be required to execute a general consent to service of process in effecting
such registration, qualification or compliance unless the Company is already subject to service in such jurisdiction and except
as may be required by the Securities Act; or

 

(b)If
a Purchaser fails to cooperate in providing the Company with all information reasonably required to be included in the Resale
Registration Statement or otherwise required to be obtained by the Company for purposes of preparing and filing the Resale Registration
Statement and any amendments thereto; provided, however, that such failure shall not affect the Company’s obligations with
respect to any Underlying Shares of any other Purchasers.

 

Once
declared effective by the Commission, the Company shall use best efforts to keep the Resale Registration Statement registering
the resale of the Underlying Shares effective during the period beginning on its effective date until the earliest of (i) such
time as all of the Common Stock and Underlying Shares shall have been sold, (ii) at least two years have passed since the Closing,
and (iii) such time as all Underlying Shares may be sold under Rule 144. For the avoidance of doubt, a Purchaser may only exercise
such resale registration rights once.

 

4.5Registration
Deadlines. If the Company fails to file a registration statement by the Resale Date, the Company shall issue to each Purchaser
a Warrant to purchase up to the number of shares of Common Stock set forth opposite such Purchaser’s name under the column
entitled “Number of Warrants Upon Failure to Register” on Schedule I attached hereto (adjusted for stock
splits, reverse stock splits and the like) at an exercise price of $5.55 per share (adjusted for stock splits, reverse stock splits
and the like) with a five year term. The Company shall issue to each Purchaser an additional Warrant to purchase up to the number
of shares of Common Stock set forth opposite such Purchaser’s name under the column entitled “Number of Warrants
Upon Failure to Register” on Schedule I attached hereto (adjusted for stock splits, reverse stock splits and
the like) for each subsequent 30 day period for which a registration statement has not been filed.

 

4.6Expenses.
The Company will pay all expenses incurred by the Company in complying with Section 4.4, including without limitation all registration
and filing fees, printing expenses (if required), fees and disbursements of counsel and independent public accountants for the
Company, fees and expenses (including reasonable counsel fees) incurred in connection with complying with state securities or
“blue sky” laws, fees of the FINRA, transfer taxes, and fees of transfer agents and registrars.

 

4.7Use
of Proceeds. The Company shall use the net proceeds from the sale of the Securities hereunder primarily for working capital
purposes and to fund the general corporate purposes of the Company and its Subsidiaries, and to fund certain contractual obligations
relating to acquisitions and to repay certain outstanding indebtedness (to the extent such indebtedness shall not have earlier
converted into common stock).

 

    	 	15	 

     

    

 

4.8Indemnification
of Purchasers. Subject to the provisions of this Section 4.8, the Company will indemnify and hold each Purchaser and its directors,
officers, stockholders, members, partners, employees and agents (and any other Persons with a functionally equivalent role of
a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser
(within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, stockholders,
agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles
notwithstanding a lack of such title or any other title) of such controlling persons (each, a “Purchaser Party”)
harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all
judgments, amounts paid in settlements, court costs and reasonable attorneys’ fees and costs of investigation that any such
Purchaser Party may suffer or incur as a result of or relating to (a) any breach of any of the representations, warranties, covenants
or agreements made by the Company in this Agreement or in the other Transaction Documents or (b) any action instituted against
the Purchaser Parties in any capacity, or any of them or their respective Affiliates, by any stockholder of the Company who is
not an Affiliate of such Purchaser Party, with respect to any of the transactions contemplated by the Transaction Documents (unless
such action is based upon a breach of such Purchaser Party’s representations, warranties or covenants under the Transaction
Documents or any agreements or understandings such Purchaser Party may have with any such stockholder or any violations by such
Purchaser Party of state or federal securities laws or any conduct by such Purchaser Party which constitutes fraud, gross negligence,
willful misconduct or malfeasance). If any action shall be brought against any Purchaser Party in respect of which indemnity may
be sought pursuant to this Agreement, such Purchaser Party shall promptly notify the Company in writing, and the Company shall
have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable to the Purchaser Party. Any
Purchaser Party shall have the right to employ separate counsel in any such action and participate in the defense thereof, but
the fees and expenses of such counsel shall be at the expense of such Purchaser Party except to the extent that (i) the employment
thereof has been specifically authorized by the Company in writing, (ii) the Company has failed after a reasonable period of time
to assume such defense and to employ counsel, or (iii) in such action there is, in the reasonable opinion of counsel, a material
conflict on any material issue between the position of the Company and the position of such Purchaser Party, in which case the
Company shall be responsible for the reasonable fees and expenses of no more than one such separate counsel in the aggregate (i.e.,
for all Purchaser Parties). The Company will not be liable to any Purchaser Party under this Agreement (y) for any settlement
by a Purchaser Party effected without the Company’s prior written consent, which shall not be unreasonably withheld or delayed,
or (z) to the extent, but only to the extent, that a loss, claim, damage or liability is attributable to any Purchaser Party’s
breach of any of the representations, warranties, covenants or agreements made by such Purchaser Party in this Agreement or in
the other Transaction Documents.

 

4.9Reservation
of Common Stock; Reporting Status. The Company shall maintain a reserve from its duly authorized shares of Common Stock for
issuance pursuant to the Transaction Documents in such amount as may then be required to issue all of the Underlying Shares. 

 

    	 	16	 

     

    

 

4.10Certain
Transactions and Confidentiality. Each Purchaser, severally and not jointly with the other Purchasers, covenants that neither
it nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including
Short Sales of any of the Company’s securities during the period commencing with the execution of this Agreement and ending
at such time that the transactions contemplated by this Agreement are first publicly announced by the Company. Each Purchaser,
severally and not jointly with the other Purchasers, covenants that until such time as the transactions contemplated by this Agreement
are publicly disclosed by the Company, such Purchaser will maintain the confidentiality of the existence and terms of this transaction
and the information included in the Transaction Documents and the Disclosure Schedules.

 

4.11Transfer
Restrictions.

 

(a)The
Securities may only be disposed of in compliance with state and federal securities laws. In connection with any transfer of any
Securities other than pursuant to an effective Resale Registration Statement or Rule 144, or to the Company, the Company may require
the transferor thereof to provide to the Company an opinion of counsel selected by the transferor and reasonably acceptable to
the Company (the fees and expenses of which shall be paid by such Purchaser), the form and substance of which opinion shall be
reasonably satisfactory to the Company, to the effect that such transfer does not require registration of such transferred Securities
under the Securities Act. As a condition of transfer, any such transferee shall agree in writing to be bound by the terms of this
Agreement and shall have the rights and obligations of a Purchaser under this Agreement.

 

(b)The
Purchasers agree to the imprinting, so long as is required by this Agreement, of a legend on any instruments evidencing the Convertible
Notes, Warrants and Underlying Shares in the following form, as applicable:

 

[NEITHER]
THIS SECURITY [NOR THE SECURITIES INTO WHICH THIS SECURITY IS [EXERCISABLE] [CONVERTIBLE]] HAS [NOT] BEEN REGISTERED WITH THE
SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER
THE SECURITIES ACT OF 1933 (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO
AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT
SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED
BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.

 

(c)Certificates
evidencing the Underlying Shares shall not contain any legend (including the legend set forth in paragraph (b) above): (i) while
a registration statement (including the Resale Registration Statement) covering the resale of such security is effective under
the Securities Act, (ii) following any sale of such Underlying Shares pursuant to Rule 144, or (iii) if such legend is not required
under applicable requirements of the Securities Act. The Company shall cause its counsel to issue a legal opinion to the Company’s
transfer agent promptly after the effective date of the Registration Statement if required by the Transfer Agent to effect the
removal of the legend hereunder. If all or any portion of a Convertible Note is converted or any portion of a Warrant is exercised
at a time when the Resale Registration Statement is effective to cover the resale of the Underlying Shares, or if such Underlying
Shares may be sold under Rule 144 or if such legend is not otherwise required under applicable requirements of the Securities
Act, then such Underlying Shares shall be issued free of all legends.

 

    	 	17	 

     

    

 

(d)Each
Purchaser, severally and not jointly with the other Purchasers, agrees with the Company that such Purchaser will sell any Securities
pursuant to either the registration requirements of the Securities Act, including, if the sale is being effected pursuant to a
registration statement (including the Resale Registration Statement), the plan of distribution contained within such registration
statement and any applicable prospectus-delivery requirements, or an exemption therefrom.

 

4.12Security
Interest. The Purchasers acknowledge that the Company has expressed its intent to grant a security interest in the assets
and properties of the Company (the “Security Interest”) to the Purchasers listed on Schedule I attached
hereto as of the date hereof, as soon as practicable following the repayment in full of the indebtedness owed by the Company to
Trooien Capital, LLC and the release, discharge and termination in full of the security interest granted in favor of Trooien Capital,
LLC in connection therewith. The Purchasers agree that the Security Interest, when granted, shall (i) secure the full and timely
payment and performance by the Company of the obligations of the Company under the Convertible Notes on a pari passu basis among
the Purchasers, and (ii) be subordinate and junior in right of payment and security to the prior payment in full of all Senior
Obligations and the liens securing the Senior Obligations. The Purchasers agree to promptly execute and deliver to each holder
of Senior Obligations, or to an agent on their behalf (individually or collectively, as applicable, the “Senior Creditor”)
such documents, agreements and instruments, and take such other actions (including, without limitation, entering into an intercreditor
agreement or subordination agreement with the Senior Creditor), as the Senior Creditor shall request to memorialize such status
of the obligations and liens, and such other arrangements as they may agree upon.

 

ARTICLE
V.

GENERAL PROVISIONS

 

5.1Additional
Purchasers. At any time and from time to time after the date hereof (whether prior to or after the Closing Date), subject
to the Company’s prior written consent:

 

(a)Additional
Person(s) may become a party to this Agreement by executing and delivering to the Company an additional counterpart signature
page to this Agreement and, upon such execution and delivery of such additional counterpart signature page, each such additional
Person shall be deemed a “Purchaser” for all purposes hereunder. No consent or approval of any other Purchaser shall
be required for such joinder to this Agreement by any additional Person, so long as such additional Person has agreed in writing
to be bound by all of the obligations as a “Purchaser” hereunder. Upon the joinder to this Agreement by an additional
Person, the Company shall be entitled to update Schedule I attached hereto to reflect the same without first obtaining
the consent or approval of any other Purchaser.

 

    	 	18	 

     

    

 

(b)Any
Purchaser may increase its Subscription Amount by executing and delivering to the Company an additional counterpart signature
page to this Agreement reflecting such increase in the Subscription Amount. No consent or approval of any other Purchaser shall
be required for any increase in the Subscription Amount of any Purchaser, and the Company shall be entitled to update Schedule
I attached hereto to reflect such increase in the Subscription Amount without first obtaining the consent or approval of any
other Purchaser.

 

5.2Fees
and Expenses. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and
expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident
to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all transfer agent
fees, stamp taxes and other taxes and duties levied in connection with the delivery of any Securities to the Purchasers.

 

5.3Entire
Agreement. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding of
the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral
or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.

 

5.4Notices.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and
shall be deemed given and effective on the earliest of: (a) the date of transmission, if such notice or communication is delivered
via facsimile at the facsimile number set forth on the signature pages attached hereto at or prior to 5:30 p.m. (Minneapolis time)
on a Trading Day, (b) the next Trading Day after the date of transmission, if such notice or communication is delivered via facsimile
at the facsimile number set forth on the signature pages attached hereto on a day that is not a Trading Day or later than 5:30
p.m. (Minneapolis time) on any Trading Day, (c) the third Trading Day following the date of mailing, if sent by U.S. nationally
recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required to be given. The
address for such notices and communications shall be as set forth on the signature pages attached hereto.

 

5.1Amendments;
Waivers. Except as provided in Section 5.1, no provision of this Agreement may be waived, modified, supplemented or amended
except in a written instrument signed, in the case of an amendment, by the Company and the Purchasers holding at least 50%
in interest of the Securities calculated based on the aggregate amount of all Subscription Amounts of the Purchasers or, in
the case of a waiver, by the party against whom enforcement of any such waived provision is sought. No waiver of any default with
respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or
a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or
omission of any party to exercise any right hereunder in any manner impair the exercise of any such right.

 

5.2Headings.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect
any of the provisions hereof.

 

5.3Successors
and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted
assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of
each Purchaser. Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom such Purchaser assigns
or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect to the transferred Securities,
by the provisions of the Transaction Documents that apply to the “Purchasers.”

 

    	 	19	 

     

    

 

5.4Third-Party
Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted
assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except for the Purchasers.

 

5.5Governing
Law. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall
be governed by and construed and enforced in accordance with the internal laws of the State of Minnesota, without regard to the
conflicts-of-law principles thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement
and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a
party hereto or its respective affiliates, directors, officers, stockholders, partners, members, employees or agents) shall be
commenced exclusively in the state and federal courts sitting in the City of Minneapolis, Minnesota. Each party hereby irrevocably
submits to the exclusive jurisdiction of the state and federal courts sitting in the City of Minneapolis, Minnesota, for the adjudication
of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including
with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert
in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such
suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal
service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered
or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under
this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing
contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either
party shall commence an action, suit or proceeding to enforce any provisions of the Transaction Documents, then the prevailing
party in such action, suit or proceeding shall be reimbursed by the other party for its reasonable attorneys’ fees and other
costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.

 

5.6Survival.
The representations and warranties contained herein shall survive the Closing and the delivery of the Securities for a one-year
period after the Closing Date.

 

5.7Execution.
This Agreement may be executed in counterparts, all of which when taken together shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood
that the parties need not sign the same counterpart. If any signature is delivered by facsimile transmission or by e-mail delivery
of a “.pdf” format data file, such signature shall create a valid and binding obligation of the party executing (or
on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf” signature
page were an original thereof.

 

    	 	20	 

     

    

 

5.8Severability.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid,
illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain
in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated
by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that
they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be
hereafter declared invalid, illegal, void or unenforceable.

 

5.9Remedies.
In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of
the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that
monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the
Transaction Documents and hereby agree to waive and not to assert in any action for specific performance of any such obligation
the defense that a remedy at law would be adequate.

 

5.10Independent
Nature of Purchasers’ Obligations and Rights. The obligations of each Purchaser under any Transaction Document are several
and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance
or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any
other Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the
Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers
are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction
Documents. Each Purchaser shall be entitled to independently protect and enforce its rights including, without limitation, the
rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser
to be joined as an additional party in any proceeding for such purpose. Each Purchaser has been represented by its own separate
legal counsel in its review and negotiation of the Transaction Documents. The Company has elected to provide all Purchasers with
the same terms and Transaction Documents for the convenience of the Company and not because it was required or requested to do
so by any of the Purchasers. It is expressly understood and agreed that each provision contained in this Agreement and in each
other Transaction Document is between the Company and a Purchaser, solely, and not between the Company and the Purchasers collectively
and not between and among the Purchasers.

 

5.11Saturdays,
Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding
Business Day.

 

5.12Construction.
The parties agree that each of them and their respective counsel have reviewed and had an opportunity to revise the Transaction
Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting
party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto.

 

5.13WAIVER
OF JURY TRIAL. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES
EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY
AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.

 

*
* * * * * *

 

    	 	21	 

     

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.

 

	CACHET
    FINANCIAL SOLUTIONS, INC.	 
	 	 	 
	By:
    	/s/
    Bryan Meier 	 
	Name:
    	Bryan
    Meier	 
	Title:
    	Chief
    Financial Officer	 

 

Address
for Notice:

 

18671
Lake Drive E.

Southwest
Tech Center A

Minneapolis,
Minnesota 55317

Facsimile:
(952) 698-6999

 

[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK

SIGNATURE
PAGE FOR PURCHASER FOLLOWS]

 

    	 	22	 

     

    

 

[PURCHASER
SIGNATURE PAGES TO SECURITIES PURCHASE AGREEMENT]

 

IN
WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.

 

Name
of Purchaser: Columbus Capital Partners, L.P.

 

Tax
ID Number/EIN: 94-3264193

 

Signature
of Authorized Signatory of Purchaser: /s/ Matt Ockner

 

Name
of Authorized Signatory: Matt Ockner

 

Title
of Authorized Signatory: Managing Member, Columbus Capital Management, LLC, General Partner

 

Email
Address of Authorized Signatory: matt@ccmfunds.com

 

Facsimile
Number of Authorized Signatory: 415-986-5130

 

Address
for Notice to Purchaser:

 

350
California St., 22nd Floor, San Francisco, CA 94104

 

Address
for Delivery of Convertible Notes and Warrants to Purchaser (if not same as address for notice):

 

 

 

Subscription
Amount: $578,000

  

	DWAC
    Instructions – Broker no: 	 	 	Account
    no: 	 	 

 

    	 	23	 

     

    

 

[PURCHASER
SIGNATURE PAGES TO SECURITIES PURCHASE AGREEMENT]

 

IN
WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.

 

Name
of Purchaser: Columbus Capital QP Partners, L.P.

 

Tax
ID Number/EIN: 45-3042671

 

Signature
of Authorized Signatory of Purchaser: /s/ Matt Ockner

 

Name
of Authorized Signatory: Matt Ockner

 

Title
of Authorized Signatory: Managing Member, Columbus Capital Management, LLC, General Partner

 

Email
Address of Authorized Signatory: matt@ccmfunds.com

 

Facsimile
Number of Authorized Signatory: 415-986-5130

 

Address
for Notice to Purchaser:

 

350
California St., 22nd Floor, San Francisco, CA 94104

 

Address
for Delivery of Convertible Notes and Warrants to Purchaser (if not same as address for notice):

 

 

 

Subscription
Amount: $122,000

 

	DWAC
    Instructions – Broker no: 	 	 	Account
    no: 	 	 

 

    	 	24	 

     

    

 

[PURCHASER
SIGNATURE PAGES TO SECURITIES PURCHASE AGREEMENT]

 

IN
WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.

 

Name
of Purchaser: FLMM Ltd.

 

Tax
ID Number/EIN: N/A

 

Signature
of Authorized Signatory of Purchaser: /s/
Per Magnus Andersson  

 

Name
of Authorized Signatory: Per Magnus Andersson

 

Title
of Authorized Signatory: President

 

Email
Address of Authorized Signatory: dmartin@kitanocapital.com

 

Facsimile
Number of Authorized Signatory: 214-515-3401

 

Address
for Notice to Purchaser:

 

2711
N. Haskell, Suite 1650, Dallas, TX 75204

 

Address
for Delivery of Convertible Notes and Warrants to Purchaser (if not same as address for notice):

 

 

 

Subscription
Amount: $1,650,000

 

	DWAC
    Instructions – Broker no: 	 	 	Account
    no: 	 	 

 

    	 	25	 

     

    

 

[PURCHASER
SIGNATURE PAGES TO SECURITIES PURCHASE AGREEMENT]

 

IN
WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.

 

Name
of Purchaser: Jon D and Linda W Gruber Trust

 

Tax
ID Number/EIN: ###-##-####

 

Signature
of Authorized Signatory of Purchaser: /s/
Jon D. Gruber  

 

Name
of Authorized Signatory: Jon D. Gruber

 

Title
of Authorized Signatory: Trustee

 

Email
Address of Authorized Signatory: jon@gmcm.com

 

Facsimile
Number of Authorized Signatory: _________________

 

Address
for Notice to Purchaser:

 

300
Tamal Plaza Ste 280, Corte Madera, CA 94925

 

Address
for Delivery of Convertible Notes and Warrants to Purchaser (if not same as address for notice):

 

 

 

Subscription
Amount: $500,000

 

	DWAC
    Instructions – Broker no: 	 	 	Account
    no: 	 	 

 

    	 	26	 

     

    

 

[PURCHASER
SIGNATURE PAGES TO SECURITIES PURCHASE AGREEMENT]

 

IN
WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.

 

Name
of Purchaser: Tiburon Opportunity Fund, L.P.

 

Tax
ID Number/EIN: 27-1985953

 

Signature
of Authorized Signatory of Purchaser: /s/ Peter Bortel

 

Name
of Authorized Signatory: Peter Bortel

 

Title
of Authorized Signatory: General Partner

 

Email
Address of Authorized Signatory: pbortel@BIM1.net

 

Facsimile
Number of Authorized Signatory: _________________

 

Address
for Notice to Purchaser:

 

Bortel
Investment Management, LLC, 13313 Point Richmond Beach Rd. NW, Gig Harbor, WA 98332

 

Address
for Delivery of Convertible Notes and Warrants to Purchaser (if not same as address for notice):

 

 

 

Subscription
Amount: $500,000

 

	DWAC
    Instructions – Broker no: 	 	 	Account
    no: 	 	 

 

    	 	27	 

     

    

 

SCHEDULE
I

 

	Purchaser	 	Note
    Principal Amount	 	 	Number
    of Warrants	 	 	Subscription
    Amount, net of Discount	 	 	Number
    of Warrants Upon Failure to Register	 
	Columbus
    Capital Partners, L.P.	 	$	608,421	 	 	 	98,663	 	 	$	578,000	 	 	 	4,933	 
	Columbus
    Capital QP Partners, L.P.	 	$	128,421	 	 	 	20,825	 	 	$	122,000	 	 	 	1,041	 
	FLMM
    Ltd.	 	$	1,736,842	 	 	 	281,650	 	 	$	1,650,000	 	 	 	14,083	 
	Tiburon
    Opportunity Fund, L.P.	 	$	526,316	 	 	 	85,349	 	 	$	500,000	 	 	 	4,267	 
	Jon
    D & Linda W Gruber Trust	 	$	526,316	 	 	 	85,349	 	 	$	500,000	 	 	 	4,267	 
	Total	 	$	3,526,316	 	 	 	571,836	 	 	$	3,350,000	 	 	 	28,591	 

 

    	 	 	 

    	 	 	 

    

 

Exhibit
A

 

NEITHER
THIS NOTE NOR THE SECURITIES THAT ARE ISSUABLE UPON CONVERSION HEREOF OR UPON EXCHANGE HEREUNDER (COLLECTIVELY, THE “SECURITIES”)
HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF
ANY STATE OR OTHER JURISDICTION. NEITHER THE SECURITIES NOR ANY INTEREST OR PARTICIPATION THEREIN MAY BE OFFERED FOR SALE, SOLD,
TRANSFERRED OR ASSIGNED: (I) IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT,
AND APPLICABLE STATE SECURITIES LAWS; OR (II) AN OPINION OF COUNSEL, IN A FORM ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS
NOT REQUIRED UNDER THE SECURITIES ACT.

 

CONVERTIBLE
TERM PROMISSORY NOTE

 

	Issuance
    Date: October _____, 2016 	[$xx]
    (USD)

 

For
Value Received, Cachet Financial Solutions, Inc.,
a corporation incorporated under the laws of the State of Delaware and located at 18671 Lake Drive East, Chanhassen, MN 55317
(the “Company”), hereby promises to pay to the order of [Insert Purchaser] or its successors or assigns
(as applicable, the “Holder”), the principal amount of [$xx] (USD), on or prior to October ____, 2017 (the
“Maturity Date”), in accordance with the terms hereof. This Convertible Term Promissory Note is hereinafter
referred to as the “Note.”

 

1.
Interest and Payments

 

1.1
Interest. The principal amount of this Note shall not bear interest.

 

1.2
Term and Payment. The principal amount of this Note shall be due and payable at the close of business on the Maturity Date.

 

1.3
Prepayment. The Company may not prepay this Note without the consent of Holder.

 

2.
Conversion Rights and Mandatory Conversion

 

Holder
will have the right, at its sole option and discretion, to convert principal and interest under this Note as specified in paragraphs
2.1 and 2.2 below.

 

2.1
Conversion Before an Event of Default. Holder shall have the right at its election to convert the principal amount of this
Note, together with accrued but unpaid interest thereon, into shares of common stock of the Company (the “Conversion
Shares”), at a conversion rate equal to the lower of (i) $7.00 per share and (ii) 80% of the Company’s per share
price in the next underwritten public offering (which for the avoidance of doubt, shall not be adjusted for stock splits, reverse
stock splits and recapitalizations occurring before the next public offering) (the “Conversion Price”).

 

    	 	 	 

    	 	 	 

    

 

2.2
Conversion After an Event of Default. After an Event of Default (as defined below), if lower, this Note shall be convertible
at a conversion price, if lower than the Conversion Price, at sixty percent (60%) of the lowest daily VWAP in the 20 trading days
immediately prior to conversion. For this purpose, “VWAP” means, for any date, the price determined by the
first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume-weighted
average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock
is then listed or quoted for trading as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time)
to 4:00 p.m. (New York City time); (b) if the Common Stock is not then quoted for trading on the OTC Bulletin Board or and if
prices for the Common Stock are then reported in the OTC Markets (or a similar organization or agency succeeding to its functions
of reporting prices), the most recent bid price per share of the Common Stock so reported; or (c) in all other cases, the fair
market value of a share of Common Stock as determined by an independent appraiser selected in good faith by Holder and reasonably
acceptable to the Company. The term “Trading Day” means a day on which the principal Trading Market is open
for business; and the term “Trading Market” means the following markets or exchanges on which the Common Stock
is listed or quoted for trading on the date in question: the American Stock Exchange, the Nasdaq Capital Market, the Nasdaq Global
Market, the Nasdaq Global Select Market, the New York Stock Exchange or the OTC Bulletin Board.

 

2.3
Manner of Conversion. Upon any exercise by the Holder of the foregoing conversion rights, the conversion of principal under
this Note shall be effected in the following manner:

 

2.3.1
The Company shall, within 20 business days of the date of the conversion (which shall be deemed effective as of the date on which
the conversion notice was given, as determined in accordance with Section 10 below), deliver to the Holder one or more certificates
representing the Conversion Shares in such name(s) and denomination(s) as the Holder shall have specified; provided, however,
that no fractional shares shall be issued in connection therewith, nor shall any transfers be permitted except in accordance with
applicable securities laws. Upon any such conversion, the number of Conversion Shares issuable shall be rounded to the nearest
whole number (with even halves rounded up).

 

2.3.2
The issuance of certificates for Conversion Shares upon a conversion shall be made without charge to the Holder in respect thereof
or other cost incurred by the Company.

 

2.3.3
All Conversion Shares issued upon a conversion hereunder shall, when so issued, be duly authorized and validly issued, fully paid
and non-assessable and free from all taxes, liens and charges. The Company shall take all such actions as may be necessary to
ensure that all such Conversion Shares may be so issued without violation of any applicable law or governmental regulation or
any requirements of any domestic securities exchange upon which such securities are quoted.

 

2.3.4If
the Company at any time after the date hereof, subdivides (by any stock split, stock dividend, recapitalization or otherwise)
one or more classes of its outstanding shares of Common Stock into a greater number of shares, the conversion price in effect
immediately prior to such subdivision will be proportionately reduced and the number of shares issued upon conversion will be
proportionately increased. If the Company at any time on or after the date hereof combines (by combination, reverse stock split
or otherwise) one or more classes of its outstanding shares of common stock into a smaller number of shares, the conversion price
in effect immediately prior to such combination will be proportionately increased. Any adjustment under this Section shall become
effective at the close of business on the date the subdivision or combination becomes effective.

 

    	 	2	 

    	 	 	 

    

 

2.4
Mandatory Conversion. Notwithstanding anything in this Note to the contrary, the Company may, in its sole discretion, require
the Holder to convert the principal amount of this Note, together with accrued but unpaid interest thereon, into Conversion Shares
if the Company’s common stock is listed on the Nasdaq Capital Market, the Nasdaq Global Market, or the Nasdaq Global Select
Market. Such mandatory conversion shall be treated as if it were a conversion pursuant to Section 2.1 above and shall be effective
as of the date of such listing.

 

3.
Transfer, Exchange and Replacement

 

3.1
Transfer or Exchange. This Note has not been and is not being registered under the provisions of the Securities Act or
any state securities laws and this Note may not be transferred prior to the end of the holding period applicable to sales under
Rule 144 unless in accordance with applicable law and unless: (1) the transferee is an “accredited investor” (as defined
in Regulation D under the Securities Act) and (2) the Holder shall have delivered to the Company an opinion of counsel, reasonably
satisfactory in form, scope and substance to the Company, to the effect that this Note may be sold or transferred without registration
under the Securities Act. Upon surrender of any Note for registration of transfer or for exchange to the Company at its principal
office, the Company at its sole expense will execute and deliver in exchange therefore a new Note or Notes, as the case may be,
as requested by the Holder or transferee, which aggregate principal amount is equal the unpaid principal amount of such Note,
registered as such Holder or transferee may request; provided, however, that this Note may not be transferred by Holder to any
Person other than Holder’s affiliates without the prior written consent of the Company. The Company shall be entitled to
regard the registered Holder of this Note as the Holder of the Note so registered for all purposes until the Company or its agent,
as applicable, is required to record a transfer of this Note on its register.

 

3.2
Replacement. Upon notice to the Company of the loss, theft, destruction or mutilation of this Note, and, in the case of
loss, theft or destruction, of an indemnification undertaking by the Holder to the Company in a form reasonably acceptable to
the Company and, in the case of mutilation, upon surrender and cancellation of the Note, the Company shall execute and deliver
a new Note of like tenor and date and in substantially the same form as this Note; provided, however, the Company shall not be
obligated to re-issue a Note if the Holder contemporaneously requests the Company to convert such remaining principal amount and
interest into Common Stock.

 

4.
Defaults and Remedies

 

The
occurrence of any one or more of the following events (regardless of the reason therefor) shall constitute an “Event
of Default” hereunder which shall be deemed to be continuing until waived in writing by Holder or until cured by the
Company:

 

(a)
the Company shall fail to pay principal on the Maturity Date;

 

    	 	3	 

    	 	 	 

    

 

(b)
a case or proceeding shall have been commenced involuntarily against the Company in a court having competent jurisdiction seeking
a decree or order under the United States Bankruptcy Code or any other applicable federal, state or foreign bankruptcy or other
similar law, and seeking either (A) the appointment of a custodian, receiver, liquidator, assignee, trustee or sequestrator (or
similar official) for such person or of any substantial part of its properties, or (B) the reorganization or winding up or liquidation
of the affairs of any such person, and such case or proceeding shall remain undismissed or unstayed for 60 consecutive days or
such court shall enter a decree or order granting the relief sought in such case or proceeding; or

 

(c)
the Company shall commence any case, proceeding or other action under any existing or future law of any jurisdiction, domestic
or foreign, relating to bankruptcy, insolvency, reorganization, conservatorship or relief of debtors, seeking to have an order
for relief entered with respect to it or seeking appointment of a custodian, receiver, liquidator, assignee, trustee or sequestrator
(or similar official) for it or any substantial part of its properties, (ii) make a general assignment for the benefit of creditors.

 

If
any Event of Default shall have occurred and be continuing, then Holder may, upon written notice to the Company, take any one
or more of the following actions: (i) declare all or any portion of the principal amount of this Note to be forthwith due and
payable, whereupon such principal shall become and be due and payable; (ii) convert this Note into Conversion Shares as provided
herein, or (iii) exercise any rights and remedies provided by law.

 

5.
Amendment and Waiver

 

The
provisions of this Note may not be modified, amended or waived, and the Company may not take any action herein prohibited, or
omit to perform any act herein required to be performed by it, without the written consent of the Holder.

 

6.
Cancellation

 

After
all principal owed on this Note has been paid in full or converted pursuant to Section 2, this Note shall automatically be deemed
canceled, and upon the Company’s request the Holder shall surrender this Note to the Company.

 

7.
Company’s Waiver of Notice

 

To
the extent permitted by law, the Company hereby waives demand, notice, protest and all other demands and notices in connection
with the delivery, acceptance, performance, default or enforcement of this Note.

 

8.
Governing Law

 

This
Note shall be construed and enforced in accordance with, and all questions concerning the construction, validity, interpretation
and performance of this Note shall be governed by, the laws of the State of Minnesota, without giving effect to provisions thereof
regarding conflict of laws.

 

    	 	4	 

    	 	 	 

    

 

9.Waiver
of Rights

 

No
failure or delay on the part of this Note in the exercise of any power, right or privilege hereunder shall operate as a waiver
thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other or further exercise thereof
or of any other right, power or privilege.

 

10.
Notices

 

Notices
shall be given at the address and as deemed for the Company or Holder, as applicable, indicated in that certain Securities Purchase
Agreement by and among the Company, Holder and the other purchasers party thereto, dated on or about the date hereof.

 

*
* * * * * *

 

    	 	5	 

    	 	 	 

    

 

In
Witness Whereof, the Company has caused this
Note to be executed as of the date first indicated above.

 

	 	CACHET
    FINANCIAL SOLUTIONS, INC.
	 	 	 
	 	By:
    	 
	 	Name:	Bryan
    Meier
	 	Title:	Chief
    Financial Officer

 

[Signature
Page to Convertible Promissory Note]

 

    	 	6	 

    	 	 	 

    

 

Exhibit
B

 

NEITHER
THIS WARRANT NOR ANY OF THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF
1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY OTHER JURISDICTION. BY ACQUIRING THIS WARRANT, HOLDER REPRESENTS THAT HOLDER
WILL NOT SELL OR OTHERWISE DISPOSE OF THIS WARRANT OR THE SECURITIES FOR WHICH IT MAY BE EXERCISED WITHOUT REGISTRATION OR COMPLIANCE
WITH AN EXEMPTION FROM REGISTRATION UNDER THE AFORESAID ACTS AND THE RULES AND REGULATIONS THEREUNDER.

 

WARRANT
TO PURCHASE COMMON STOCK

 

Number
of Shares of Common Stock: [xx]

Date
of Issuance: October ___, 2016 (“Issuance Date”)

 

This
Certifies That, for value received, [Insert
Purchaser] (including any permitted and registered assigns, the “Holder”), is entitled to purchase from
Cachet Financial Solutions, Inc., a Delaware corporation (the “Company”), up to [xx] shares of Common Stock
(the “Warrant Shares”) at the Exercise Price then in effect. This Warrant to Purchase Common Stock (this “Warrant”)
is issued by the Company pursuant to that certain Securities Purchase Agreement executed on the Issuance Date by and among the
Company, Holder and other parties thereto, if any (the “Purchase Agreement”).

 

Capitalized
terms used in this Warrant shall have the meanings set forth in the Purchase Agreement unless otherwise defined in the body of
this Warrant or in Section 13 below. For purposes of this Warrant, the term “Exercise Price” shall mean the
lower of (i) $5.55 per share and (ii) 80% of the Company’s per share price in the next underwritten public offering (which
for the avoidance of doubt, shall not be adjusted for stock splits, reverse stock splits and recapitalizations occurring before
the next public offering), subject to adjustment as provided herein, and the term “Exercise Period” shall mean
the period commencing on the Issuance Date and ending on 5:00 p.m. New York time on the five-year anniversary thereof.

 

1.EXERCISE
OF WARRANT.

 

(a)Mechanics
of Exercise. Subject to the terms and conditions hereof, the rights represented by this Warrant may be exercised in whole
or in part at any time or times during the Exercise Period by delivery of a written notice, in the form attached hereto as Exhibit
A (the “Exercise Notice”), of the Holder’s election to exercise this Warrant. The Holder shall not
be required to deliver the original Warrant in order to effect an exercise hereunder. Execution and delivery of the Exercise Notice
with respect to less than all of the Warrant Shares shall have the same effect as cancellation of the original Warrant and issuance
of a new Warrant evidencing the right to purchase the remaining number of Warrant Shares. On or before the third Trading Day (the
“Warrant Share Delivery Date”) following the date on which the Company shall have received the Exercise Notice,
and upon receipt by the Company of (i) payment to the Company of an amount equal to the applicable Exercise Price multiplied by
the number of Warrant Shares as to which this Warrant is being exercised (the “Aggregate Exercise Price” and
together with the Exercise Notice, the “Exercise Delivery Documents”) in cash or by wire transfer of immediately
available funds or (ii) notification from the Holder that this Warrant is being exercised pursuant to a Cashless Exercise, as
defined below, the Company shall (or direct its transfer agent to) issue and dispatch by overnight courier to the address as specified
in the Exercise Notice, a certificate, registered in the Company’s share register in the name of the Holder or its designee,
for the number of shares of Common Stock to which the Holder is entitled pursuant to such exercise. Upon delivery of the Exercise
Delivery Documents, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares
with respect to which this Warrant has been exercised, irrespective of the date of delivery of the certificates evidencing such
Warrant Shares. If this Warrant is submitted in connection with any exercise pursuant to Section 1(c) and the number of Warrant
Shares represented by this Warrant submitted for exercise is greater than the number of Warrant Shares being acquired upon an
exercise, then the Company shall as soon as practicable and in no event later than three Business Days after any exercise and
at its own expense, issue a new Warrant (in accordance with Section 6) representing the right to purchase the number of Warrant
Shares purchasable immediately prior to such exercise under this Warrant, less the number of Warrant Shares with respect to which
this Warrant is exercised.

 

    	 	 	 

    	 	 	 

    

 

(b)No
Fractional Shares. No fractional shares shall be issued upon the exercise of this Warrant as a consequence of any adjustment
pursuant hereto. All Warrant Shares (including fractions) issuable upon exercise of this Warrant may be aggregated for purposes
of determining whether the exercise would result in the issuance of any fractional share. If, after aggregation, the exercise
would result in the issuance of a fractional share, the Company shall, in lieu of issuance of any fractional share, pay the Holder
otherwise entitled to such fraction a sum in cash equal to the product resulting from multiplying the then-current fair market
value of a Warrant Share by such fraction.

 

(c)Cashless
Exercise. The Holder may, in its sole discretion, at any time prior to the effective date of a registration statement filed
by the Company or any Subsidiary under the Securities Act covering the Warrant Shares, exercise this Warrant in whole or in part
and, in lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise in payment of the
Aggregate Exercise Price, elect instead to receive upon such exercise the “Net Number” of shares of Common
Stock determined according to the following formula (a “Cashless Exercise”):

 

Net
Number = (A x B) - (A x C)

B

 

For
purposes of the foregoing formula:

 

	 	A
    =	the
    total number of shares with respect to which this Warrant is then being exercised.
	 	 	 
	 	B
    = 	the
    Weighted Average Price of the shares of Common Stock for the five consecutive Trading Days ending on the date immediately
    preceding the date of the Exercise Notice.
	 	 	 
	 	C
    = 	the
    Exercise Price then in effect for the applicable Warrant Shares at the time of such exercise.

 

    	 	2	 

    	 	 	 

    

 

(d)Holder’s
Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to
exercise any portion of this Warrant, to the extent that after giving effect to issuance of Warrant Shares upon exercise as set
forth on the applicable Notice of Exercise, the Holder (together with the Holder’s Affiliates, and any other persons acting
as a group together with the Holder or any of the Holder’s Affiliates), would beneficially own in excess of the Beneficial
Ownership Limitation, as defined below. For purposes of the foregoing sentence, the number of shares of Common Stock beneficially
owned by the Holder and its Affiliates shall include the number of shares of Common Stock issuable upon exercise of this Warrant
with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be
issuable upon (i) exercise of the remaining, non-exercised portion of this Warrant beneficially owned by the Holder or any of
its Affiliates and (ii) exercise or conversion of the unexercised or non-converted portion of any other securities of the Company
(including without limitation any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous
to the limitation contained herein beneficially owned by the Holder or any of its Affiliates. Except as set forth in the preceding
sentence, for purposes of this paragraph (d), beneficial ownership shall be calculated in accordance with Section 13(d) of the
Exchange Act, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is
in compliance with Section 13(d) of the Securites Exchange Act of 1934, as amended, and the Holder is solely responsible for any
schedules required to be filed in accordance therewith. To the extent that the limitation contained in this paragraph applies,
the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any
affiliates) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission
of a Notice of Exercise shall be deemed to be the Holder’s determination of whether this Warrant is exercisable (in relation
to other securities owned by the Holder together with any Affiliates) and of which portion of this Warrant is exercisable, in
each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy
of such determination.

 

For
purposes of this paragraph, in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of
outstanding shares of Common Stock as reflected in (A) the Company’s most recent periodic or annual report filed with the
Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the
Company or its transfer agent setting forth the number of shares of Common Stock outstanding. Upon the request of a Holder, the
Company shall within two Trading Days confirm to the Holder the number of shares of Common Stock then outstanding. In any case,
the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities
of the Company, including this Warrant, by the Holder or its affiliates since the date as of which such number of outstanding
shares of Common Stock was reported. The “Beneficial Ownership Limitation” shall be 4.99% of the number of
shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon
exercise of this Warrant. Upon no fewer than 61 days’ prior notice to the Company, a Holder may increase or decrease the
Beneficial Ownership Limitation provisions of this paragraph, provided that the Beneficial Ownership Limitation in no event exceeds
9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common
Stock upon exercise of this Warrant held by the Holder and the provisions of this paragraph shall continue to apply. Any such
increase or decrease will not be effective until the 61st day after such notice is delivered to the Company and shall only apply
to such Holder and no other Holder. The limitations contained in this paragraph shall apply to a successor Holder of this Warrant.

 

    	 	3	 

    	 	 	 

    

 

2.ADJUSTMENTS.
The Exercise Price and the number of Warrant Shares shall be adjusted from time to time as follows:

 

(a)Subdivision
or Combination of Common Stock. If the Company at any time on or after the Issuance Date subdivides (by any stock split, stock
dividend, recapitalization or otherwise) one or more classes of its outstanding shares of Common Stock into a greater number of
shares, the Exercise Price in effect immediately prior to such subdivision will be proportionately reduced and the number of Warrant
Shares will be proportionately increased. If the Company at any time on or after the Issuance Date combines (by combination, reverse
stock split or otherwise) one or more classes of its outstanding shares of Common Stock into a smaller number of shares, the Exercise
Price in effect immediately prior to such combination will be proportionately increased and the number of Warrant Shares will
be proportionately decreased. Any adjustment under this Section shall become effective at the close of business on the date the
subdivision or combination becomes effective.

 

(b)Distribution
of Assets. If the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its
assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including without limitation any distribution
of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement
or other similar transaction) (a “Distribution”), at any time after the issuance of this Warrant, then, in
each such case:

 

(i)any
Exercise Price in effect immediately prior to the close of business on the record date fixed for the determination of holders
of shares of Common Stock entitled to receive the Distribution shall be reduced, effective as of the close of business on such
record date, to a price determined by multiplying such Exercise Price by a fraction (i) the numerator of which shall be the Closing
Sale Price of the shares of Common Stock on the Trading Day immediately preceding such record date minus the value of the Distribution
(as determined in good faith by the Company’s Board of Directors) applicable to one share of Common Stock, and (ii) the
denominator of which shall be the Closing Sale Price of the shares of Common Stock on the Trading Day immediately preceding such
record date; and

 

(ii)the
number of Warrant Shares shall be increased to a number of shares equal to the number of shares of Common Stock obtainable immediately
prior to the close of business on the record date fixed for the determination of holders of shares of Common Stock entitled to
receive the Distribution multiplied by the reciprocal of the fraction set forth in the immediately preceding clause (i); provided,
however, that in the event that the Distribution is of shares of common stock of a company (other than the Company) whose common
stock is traded on a national securities exchange or a national automated quotation system (“Other Shares of Common Stock”),
then the Holder may elect to receive a warrant to purchase Other Shares of Common Stock in lieu of an increase in the number of
Warrant Shares, the terms of which shall be identical to those of this Warrant, except that such warrant shall be exercisable
into the number of shares of Other Shares of Common Stock that would have been payable to the Holder pursuant to the Distribution
had the Holder exercised this Warrant immediately prior to such record date and with an aggregate exercise price equal to the
product of the amount by which the exercise price of this Warrant was decreased with respect to the Distribution pursuant to the
terms of the immediately preceding clause (i) and the number of Warrant Shares calculated in accordance with the first part of
this clause (ii).

 

    	 	4	 

    	 	 	 

    

 

3.FUNDAMENTAL
TRANSACTIONS. If, at any time while this Warrant is outstanding, (i) the Company effects any merger of the Company with or
into another entity and the Company is not the surviving entity (such surviving entity, the “Successor Entity”),
(ii) the Company effects any sale of all or substantially all of its assets in one or a series of related transactions, (iii)
any tender offer or exchange offer (whether by the Company or by another individual or entity, and approved by the Company) is
completed pursuant to which holders of Common Stock are permitted to tender or exchange their shares of Common Stock for other
securities, cash or property and the holders of at least 50% of the Common Stock accept such offer, or (iv) the Company effects
any reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted
into or exchanged for other securities, cash or property (other than as a result of a subdivision or combination of shares of
Common Stock covered by Section 2(a) above) (in any such case, a “Fundamental Transaction”), then, upon any
subsequent exercise of this Warrant, the Holder shall have the right to receive the number of shares of Common Stock of the Successor
Entity or of the Company and any additional consideration (the “Alternate Consideration”) receivable upon or
as a result of such reorganization, reclassification, merger, consolidation or disposition of assets by a holder of the number
of shares of Common Stock for which this Warrant is exercisable immediately prior to such event (disregarding any limitation on
exercise contained herein solely for the purpose of such determination). For purposes of any such exercise, the determination
of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate
Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion
the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components
of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received
in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon
any exercise of this Warrant following such Fundamental Transaction. To the extent necessary to effectuate the foregoing provisions,
any Successor Entity in such Fundamental Transaction shall issue to the Holder a new warrant consistent with the foregoing provisions
and evidencing the Holder’s right to exercise such warrant into Alternate Consideration.

 

4.NON-CIRCUMVENTION.
The Company covenants and agrees that it will not, by amendment of its certificate of incorporation, bylaws or through any reorganization,
transfer of assets, consolidation, merger, scheme of arrangement, dissolution, issue or sale of securities, or any other voluntary
action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, and will at all times in good
faith carry out all the provisions of this Warrant and take all action as may be required to protect the rights of the Holder.
Without limiting the generality of the foregoing, the Company (i) shall not increase the par value of any shares of Common Stock
receivable upon the exercise of this Warrant above the Exercise Price then in effect, (ii) shall take all such actions as may
be necessary or appropriate in order that the Company may validly and legally issue fully paid and non-assessable shares of Common
Stock upon the exercise of this Warrant, and (iii) shall, for so long as this Warrant is outstanding, have authorized and reserved,
free from preemptive rights, a sufficient number of shares of Common Stock to provide for the exercise of the rights represented
by this Warrant (without regard to any limitations on exercise).

 

    	 	5	 

    	 	 	 

    

 

5.WARRANT
HOLDER NOT DEEMED A STOCKHOLDER. Except as otherwise specifically provided herein, this Warrant, in and of itself, shall not
entitle the Holder to any voting rights or other rights as a stockholder of the Company. In addition, nothing contained in this
Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this Warrant
or otherwise) or as a stockholder of the Company, whether such liabilities are asserted by the Company or by creditors of the
Company.

 

6.REISSUANCE.

 

(a)Lost,
Stolen or Mutilated Warrant. If this Warrant is lost, stolen, mutilated or destroyed, the Company will, on such terms as to
indemnity or otherwise as it may reasonably impose (which shall, in the case of a mutilated Warrant, include the surrender thereof),
issue a new Warrant of like denomination and tenor as this Warrant so lost, stolen, mutilated or destroyed.

 

(b)Issuance
of New Warrants. Whenever the Company is required to issue a new Warrant pursuant to the terms of this Warrant, such new Warrant
shall be of like tenor with this Warrant, and shall have an issuance date, as indicated on the face of such new Warrant which
is the same as the Issuance Date.

 

7.TRANSFER.

 

(a)Notice
of Transfer. The Holder agrees to give written notice to the Company before transferring this Warrant or transferring any
Warrant Shares of such Holder’s intention to do so, describing briefly the manner of any proposed transfer. Promptly upon
receiving such written notice, the Company shall present copies thereof to the Company’s counsel. If the proposed transfer
may be effected without registration or qualification (under any federal or state securities laws), the Company, as promptly as
practicable, shall notify the Holder thereof, whereupon the Holder shall be entitled to transfer this Warrant or to dispose of
Warrant Shares received upon the previous exercise of this Warrant, all in accordance with the terms of the notice delivered by
the Holder to the Company; provided, however, that an appropriate legend may be endorsed on this Warrant or the certificates for
such Warrant Shares respecting restrictions upon transfer thereof necessary or advisable in the opinion of counsel and satisfactory
to the Company to prevent further transfers which would be in violation of Section 5 of the Securities Act and applicable state
securities laws; and provided further that the prospective transferee or purchaser shall execute the Assignment of Warrant attached
hereto as Exhibit B and such other documents and make such representations, warranties, and agreements as may be required
solely to comply with the exemptions relied upon by the Company for the transfer or disposition of the Warrant or Warrant Shares.

 

(b)If
the proposed transfer or disposition of this Warrant or such Warrant Shares described in the written notice given pursuant to
this Section 7 may not be effected without registration or qualification of this Warrant or such Warrant Shares, the Holder will
limit its activities in respect to such transfer or disposition as are permitted by law.

 

    	 	6	 

    	 	 	 

    

 

(c)Any
transferee of all or a portion of this Warrant shall succeed to the rights and benefits of the initial Holder of this Warrant
under Sections 4.1 and 4.3 (subject, however, to the limitations set forth in Section 4.2), 4.4 and 4.5 of the Purchase Agreement
(registration rights, expenses, and indemnity).

 

8.NOTICES.
Whenever notice is required to be given under this Warrant, unless otherwise provided herein, such notice shall be given in accordance
with the notice provisions contained in the Purchase Agreement. The Company shall provide the Holder with prompt written notice
(i) immediately upon any adjustment of the Exercise Price, setting forth in reasonable detail, the calculation of such adjustment
and (ii) at least 20 days prior to the date on which the Company closes its books or takes a record (A) with respect to any dividend
or distribution upon the shares of Common Stock, (B) with respect to any grants, issuances or sales of any stock or other securities
directly or indirectly convertible into or exercisable or exchangeable for shares of Common Stock or other property, pro rata
to the holders of shares of Common Stock or (C) for determining rights to vote with respect to any Fundamental Transaction, dissolution
or liquidation, provided in each case that such information shall be made known to the public prior to or in conjunction with
such notice being provided to the Holder.

 

9.AMENDMENT
AND WAIVER. The terms of this Warrant may be amended or waived (either generally or in a particular instance and either retroactively
or prospectively) only with the written consent of the Company and the Holder. In addition, the restrictions set forth in Section
1(d) can be waived, as to a particular original purchaser of Common Stock and its affiliates, pursuant to a writing signed and
delivered by the Company and such original Purchaser prior to the execution and delivery of this Warrant.

 

10.GOVERNING
LAW. This Warrant and all rights, obligations and liabilities hereunder shall be governed by, and construed in accordance
with, the internal laws of the State of Minnesota, without giving effect to the conflicts-of-law principles thereof.

 

11.DISPUTE
RESOLUTION. A dispute as to the determination of the Exercise Price, the Closing Sale Price, or the arithmetic calculation
of the Warrant Shares, the Company or the Holder (as the case may be) shall submit the disputed determinations or arithmetic calculations
via facsimile (a) within two Business Days after receipt of the applicable notice giving rise to such dispute to the Company or
the Holder, as the case may be, or (b) if no notice gave rise to such dispute, at any time after the Holder learned of the circumstances
giving rise to such dispute. If the Holder and the Company are unable to agree upon such determination or calculation of the Exercise
Price, Closing Sale Price or the Warrant Shares within three Business Days of such disputed determination or arithmetic calculation
being submitted to the Company or the Holder, as the case may be, then the Company shall, within two Business Days thereafter
submit via facsimile (x) the disputed determination of the Exercise Price or Closing Sale Price to an independent, reputable investment
bank selected by the Company and approved by the Holder or (y) the disputed arithmetic calculation of the Warrant Shares to the
Company’s independent, outside accountant. The Company shall cause at its expense the investment bank or the accountant,
as the case may be, to perform the determinations or calculations and notify the Company and the Holder of the results no later
than ten Business Days from the time it receives the disputed determinations or calculations. Such investment bank’s or
accountant’s determination or calculation, as the case may be, shall be binding upon all parties absent manifest error.

 

    	 	7	 

    	 	 	 

    

 

12.ACCEPTANCE.
Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and conditions contained
herein.

 

13.CERTAIN
DEFINITIONS. For purposes of this Warrant, the following terms shall have the following meanings:

 

(a)“Bloomberg”
means Bloomberg Financial Markets.

 

(b)“Closing
Sale Price” means, for any security as of any date, (i) the last closing trade price for such security on the Principal
Market, as reported by Bloomberg, or, if the Principal Market begins to operate on an extended hours basis and does not designate
the closing trade price, then the last trade price of such security prior to 4:00 p.m., New York time, as reported by Bloomberg,
or (ii) if the foregoing does not apply, the last trade price of such security in the over-the-counter market for such security
as reported by Bloomberg, or (iii) if no last trade price is reported for such security by Bloomberg, the average of the bid and
ask prices of any market makers for such security as reported by the OTC Markets. If the Closing Sale Price cannot be calculated
for a security on a particular date on any of the foregoing bases, the Closing Sale Price of such security on such date shall
be the fair market value as mutually determined by the Company and the Holder. All such determinations to be appropriately adjusted
for any stock dividend, stock split, stock combination or other similar transaction during the applicable calculation period.

 

(c)“Common
Stock” means the Company common stock, par value $0.0001 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.

 

(d)“Common
Stock Equivalents” means any securities of the Company that would entitle the holder thereof to acquire at any time
Common Stock, including without limitation any debt, preferred stock, rights, options, warrants or other instrument that is at
any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.

 

(e)“Principal
Market” means the primary national securities exchange on which the Common Stock is then traded.

 

(f)“Trading
Day” means (i) any day on which the Common Stock is listed or quoted and traded on its Principal Market, (ii) if the
Common Stock is not then listed or quoted and traded on any national securities exchange, then a day on which trading occurs on
any over-the-counter markets, or (iii) if trading does not occur on the over-the-counter markets, any Business Day.

 

*
* * * * * *

 

    	 	8	 

    	 	 	 

    

 

In
Witness Whereof, the Company has caused this
Warrant to Purchase Common Stock to be duly executed as of the Issuance Date set forth above.

 

	 	CACHET
    FINANCIAL SOLUTIONS, INC.
	 	 
	 	 
	 	Bryan
    Meier
	 	Executive
    Vice President & Chief Financial Officer

 

    	 	 	 

    	 	 	 

    

 

EXHIBIT
A

 

EXERCISE
NOTICE

 

(To
be executed by the registered holder to exercise this Warrant to Purchase Common Stock)

 

The
Undersigned holder hereby exercises the right
to purchase _________________ of the shares of Common Stock (“Warrant Shares”) of Cachet Financial Solutions, Inc.,
a Delaware corporation (the “Company”), evidenced by the attached copy of the Warrant to Purchase Common Stock (the
“Warrant”). Capitalized terms used herein and not otherwise defined shall have the respective meanings set forth in
the Warrant.

 

	1.	Form
    of Exercise Price. The Holder intends that payment of the Exercise Price shall be made as (check one):

 

	 	[  ]	a
    cash exercise with respect to _________________ Warrant Shares; and/or 
	 	 	 
	 	[  ]	a
    “Cashless Exercise” with respect to _______________ Warrant Shares. 

 

	2.	Payment
    of Exercise Price. In the event that the holder has elected a cash exercise with respect to some or all of the Warrant
    Shares to be issued pursuant hereto, the holder shall pay the Aggregate Exercise Price in the sum of $___________________
    to the Company in accordance with the terms of the Warrant.
	 	 
	3.	Delivery
    of Warrant Shares. The Company shall deliver to the holder __________________ Warrant Shares in accordance with the terms
    of the Warrant. 

 

	Date:	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	(Print
    Name of Registered Holder) 
	 	 	 	 	 
	 	 	 	By:
    	               
	 	 	 	Name:
    	 
	 	 	 	Title:
    	 

 

    	 	 	 

    	 	 	 

    

 

EXHIBIT
B

 

ASSIGNMENT
OF WARRANT

 

(To
be signed only upon authorized transfer of the Warrant)

 

For
Value Received, the undersigned hereby sells,
assigns, and transfers unto ____________________ the right to purchase _______________ shares of common stock of Cachet Financial
Solutions, Inc., to which the within Warrant to Purchase Common Stock relates and appoints ____________________, as attorney-in-fact,
to transfer said right on the books of Cachet Financial Solutions, Inc. with full power of substitution and re-substitution in
the premises. By accepting such transfer, the transferee has agreed to be bound in all respects by the terms and conditions of
the within Warrant.

 

	Dated:	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	(Signature)
    *
	 	 	 	 
	 	 	 	 
	 	 	 	(Name)
    
	 	 	 	 
	 	 	 	 
	 	 	 	(Address)
	 	 	 	 
	 	 	 	 
	 	 	 	(Social
    Security or Tax Identification No.) 

 

*
The signature on this Assignment of Warrant must correspond to the name as written upon the face of the Warrant to Purchase Common
Stock in every particular without alteration or enlargement or any change whatsoever. When signing on behalf of a corporation,
partnership, trust or other entity, please indicate your position(s) and title(s) with such entity.Exhibit 10.1

 

AMENDED AND RESTATED

DISTRIBUTION AND LICENSE AGREEMENT

by and between

MEDIZONE INTERNATIONAL, INC.

and

GYD S.A.

 

This Amended and Restated Distribution and License Agreement (“Agreement”), effective as of October 21, 2016, is entered into by Medizone International, Inc., a Nevada corporation, with its principal executive offices at 4000 Bridgeway, Suite 401, Sausalito, California 94965, USA (“Medizone”), and GYD S.A., a corporation formed under the laws of Chile, with its principal place of business at Los Cactus 1558, Lo Barnechea, Santiago, Chile (“Distributor”).

 

RECITALS:

 

A.          Medizone is in the business of developing and selling portable, low-cost, ozone-based technology products (“AsepticSure®”) specifically for multiple applications and fields of use, including but not limited to, the decontaminating and disinfection of hospital surgical suites, emergency rooms, and intensive care units, and is the owner of certain trade secrets, patent rights, trademarks, copyrights and other Intellectual Property rights related thereto.

B.          Distributor desires (i) to acquire the right to purchase Products (as defined herein) from Medizone as equipment and supplies mainly for its proposed service business, as such business has been disclosed and presented to Medizone (the “Service Business”), and (ii) to license from Medizone certain rights and authority to distribute and re-sell the Products, and Medizone desires to grant Distributor such rights and license, pursuant to the terms and conditions of this Agreement.

C.          WHEREAS, the Parties have previously executed an International Distribution and License Agreement effective as of November 12, 2015 (the “Prior Agreement”); and

D.          WHEREAS the Parties now wish to modify and expand their relationship, and they have thus set forth the terms of their expanded relationship within this Agreement below, with the intent and desire that this Agreement shall replace and supersede the Prior Agreement;

 

NOW THEREFORE, the Parties agree as follows:

AGREEMENTS:

	
1.

	
General Definitions.

 

	
(a)

	
“Affiliate” of a Person means any other Person that directly or indirectly, through one or more intermediaries, Controls, is Controlled by, or is under common Control with, this Person.

 

	
(b)

	
“Agreement” has the meaning set out in the preamble.

	
(c)

	
“Business Day” means any day except Saturday, Sunday or a federal or California holiday.

 

	
(d)

	
“Confidential Information” means information about a Person’s business affairs, goods and services, confidential information and materials comprising or relating to Intellectual Property Rights, trade secrets, third-party confidential information and other sensitive or proprietary information; such information, as well as the terms of this Agreement, whether orally or in written, electronic or other form or media, and whether or not marked, designated or otherwise identified as “confidential.” Confidential Information excludes information that, at the time of disclosure:

 

	
(i)

	
is or becomes generally available to and known by the public other than as a result of, directly or indirectly, any breach of this Agreement by the recipient (“Receiving Party”) or any of its Representatives;

 

	
(ii)

	
is or becomes available to Receiving Party on a non-confidential basis from a third-party source, provided that such third party is not and was not prohibited from disclosing such Confidential Information;

 

	
(iii)

	
was known by or in the possession of Receiving Party or its Representatives before being disclosed by or on behalf of the Party disclosing such Confidential Information (“Disclosing Party”);

 

	
(iv)

	
was or is independently developed by Receiving Party without reference to or use of, in whole or in part, any of Disclosing Party’s Confidential Information; or

 

	
(v)

	
must be disclosed under applicable Law.

 

	
(e)

	
“Control” (and with correlative meanings, the terms “Controlled by” and “under common Control with”) means, regarding any Person, the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of another Person, whether through the ownership or voting securities, by contract, or otherwise.

 

	
(f)

	
“Customer” means a purchaser of Products located in the Territory.

 

	
(g)

	
“Defective” means not conforming to the warranties offered by Medizone.

 

	
(h)

	
“Defective Product” means Products that are Defective.

 

	
(i)

	
“Distributor” has the meaning set out in the preamble of this Agreement.

 

	
(j)

	
“Effective Date” means the date first set forth above.

 

	
(k)

	
“Force Majeure Event” has the meaning set out in Section 32(d).

 

	
(l)

	
“Governmental Authority” means any federal, state, local or foreign government or political subdivision thereof, or any agency or instrumentality of the government or political subdivision, or any self-regulated organization or other non-governmental regulatory authority or quasi-governmental authority (to the extent that the rules, regulations or orders of this organization or authority have the force of Law), or any arbitrator, court or tribunal of competent jurisdiction.

Page 2 of 30

	
(m)

	
“Governmental Order” means any order, writ, judgment, injunction, decree, stipulation, award or determination entered by or with any Governmental Authority.

 

	
(n)

	
“Initial Term” has the meaning set out in Section 18.1.

 

	
(o)

	
“Intellectual Property Rights” means all industrial and other intellectual property rights comprising or relating to: (i) Patents; (ii) Trademarks; (iii) internet domain names, whether or not Trademarks, registered by any authorized private registrar or Governmental Authority, web addresses, web pages, website and URLs; (iv) works of authorship, expressions, designs and design registrations, whether or not copyrightable, including copyrights and copyrightable works, software and firmware, application programming interfaces, architecture, files, records, schematics, data, data files, and databases and other specifications and documentation; (v) Trade Secrets; (vi) semiconductor chips, mask works and the like; and (vii) all industrial and other intellectual property rights, and all rights, interests and protections that are associated with, equivalent or similar to, or required for the exercise of, any of the foregoing, however arising, in each case whether registered or unregistered and including all registrations and applications for, and renewals or extensions of, these rights or forms of protection under the Laws of any jurisdiction throughout in any part of the world.

 

	
(p)

	
“Law” means any statute, law, ordinance, regulation, rule, code, constitution, treaty, common law, Governmental Order or other requirement or rule of law of any Governmental Authority.

 

	
(q)

	
“NFR Product” means Products provided to Distributor by Medizone that are not to be used for training, demonstration and other purposes and are not for resale in the Territory.  Notwithstanding anything on the contrary NFR Product does not include Products purchased by Distributor to perform the Service Business.

 

	
(r)

	
“Nonconforming Goods” means any goods received by Distributor from Medizone under a Purchase Order that: (a) is not a Product; (b) does not conform to the specifications listed in the applicable Purchase Order; or (c) on visual inspection, Distributor reasonably determines are otherwise Defective.

 

	
(s)

	
“Notice” has the meaning set out in Section 32(f).

 

	
(t)

	
“Notify” means to give Notice.

 

	
(u)

	
“Party” has the meaning set out in the preamble to this Agreement.

 

	
(v)

	
“Patents” means all patents (including all reissues, divisionals, provisionals, continuations and continuations-in-part, re-examinations, renewals, substitutions and extensions thereof), patent applications, and other patent rights and any other Governmental Authority-issued indicia of invention ownership (including inventor’s certificates, petty patents and patent utility models).

 

	
(w)

	
“Payment Failure” has the meaning set out in Section 18.4.

 

	
(x)

	
“Person” means any individual, partnership, corporation, trust, limited liability entity, unincorporated organization, association, Governmental Authority or any other entity.

Page 3 of 30

	
(y)

	
“Personnel” means agents, employees or subcontractors engaged or appointed by Medizone or Distributor.

 

	
(z)

	
“Post-term Sale Period” has the meaning set out in Section 18.3.

 

	
(aa)

	
“Price” means the purchase price of the Products set forth on Exhibit A.

 

	
(bb)

	
“Products” means the AsepticSure products and supplies, and successor products and supplies to the current AsepticSure, including, but not limited to, improvements, modifications, supplementations and enhancements to the current version of the Products offered in the future by Medizone. “Products” shall also include any additional products that the Parties agree in writing to add as Products under the terms of this Agreement.

 

	
(cc)

	
“Purchase Order” means Distributor’s then-current standard form purchase order.

 

	
(dd)

	
“Purchase Order Transaction Terms” means any one or more of the terms specified by Distributor in a Purchase Order. For the avoidance of doubt, the term Purchase Order Transaction Terms does not include any general terms or conditions of any Purchase Order.

 

	
(ee)

	
“Receiving Party” has the meaning set out in Section 1(d)(i).

 

	
(ff)

	
“Renewal Term” has the meaning set out in Section 18.2.

 

	
(gg)

	
“Representatives” means a Party’s Affiliates, employees, officers, directors, partners, shareholders, agents, attorneys, third-party advisors, successors and permitted assigns.

 

	
(hh)

	
“Term” has the meaning set out in Section 18.1.

 

	
(ii)

	
“Territory” has the meaning set out in Exhibit B.

 

	
(jj)

	
“Third Party Product” has the meaning set out in Section 26.

 

	
(kk)

	
“Trademarks” means all rights in and to US and foreign trademarks, service marks, trade dress, trade names, brand names, logos, trade dress, corporate names and domain names and other similar designations of source, sponsorship, association or origin, together with the goodwill symbolized by any of the foregoing, in each case whether registered or unregistered and including all registrations and applications for, and renewals or extensions of, these rights and all similar or equivalent rights or forms of protection in any part of the world.

 

	
(ll)

	
“Trade Secrets” means all inventions, discoveries, trade secrets, business and technical information and know-how, databases, data collections, patent disclosures and other confidential and proprietary information and all rights therein.

 

	
(mm)

	
“US” means the United States of America, including its territories, possessions and military bases.

 

	
2.

	
Grant of Rights.

 

	
(a)

	
Grant of Rights.  Medizone hereby appoints Distributor, and Distributor accepts the appointment, to act as a distributor of the Products to Customers located in the Territory during the Term and the Post-term Sale Period solely in accordance with

Page 4 of 30

the terms and conditions of this Agreement. Distributor shall also have the right to purchase Products from Medizone for its proposed Service Business according to this Agreement.  Medizone may in its sole discretion sell the Product to any other Person outside the Territory; provided, however, that Medizone will not solicit Customers in the Territory and will refer promptly all inquiries for sales within the Territory to Distributor.  In the event Distributor’s rights under this Agreement shall be deemed non-exclusive as to any part of the Territory pursuant to the exercise of the rights of Medizone or any successor in interest to Medizone under Section 6(a) herein, Medizone and/or its successors in interest shall not solicit Distributor’s Customers who are documented to have purchased or leased Products or Services from Distributor during the Term of this Agreement within the Territory and who have no history of warranty or unreasonable product returns or service records.  Distributor will not solicit sales of or sell Products outside the Territory and will refer promptly all inquiries for the sale of the Products outside the Territory to Medizone.    By accepting this appointment, Distributor agrees to conform to all reasonable quality standards established from time to time by Medizone for its distributors worldwide. These quality standards are subject to change by Medizone on 15 Business Days’ prior Notice to Distributor.

 

	
(b)

	
Exclusivity of Appointment.  Notwithstanding anything to the contrary in this Agreement, but subject to Medizone’s rights set forth in Section 6(a) herein:  Distributor’s appointment in Section 2(a), above, shall be exclusive as to Third Parties within the Territory. As used in this Agreement, “exclusive” means that Medizone shall not, during the Term, have any right to make, have made, market, distribute, sell or otherwise commercially exploit the Products in the Territory or to authorize any affiliate or third party to do so.  Medizone undertakes not to appoint any third party to import, market and distribute the Products in the Territory, nor will it import, market, distribute or sell the Products itself to Customers in the Territory.  Medizone agrees that it will not appoint another distributor within the Territory so long as this Agreement remains in force. Medizone will prohibit its distributors outside the Territory from soliciting Customers and selling to Customers within the Territory.  Medizone’s written agreements with Customers will provide that such Customers and any of their affiliates are prohibited from marketing, distributing, selling or otherwise commercially exploiting the Products in the Territory.

 

	
(c)

	
No Right to Appoint a Subdistributor. Distributor shall not, without the prior written consent of Medizone, which shall not be unreasonably withheld:

 

	
(i)

	
appoint any subdistributor or other Person or entity to sell or distribute Product at the wholesale level; or

 

	
(ii)

	
sell the Product to any person or entity who Distributor knows or has reason to believe is purchasing Product for resale other than at retail to Customers within the Territory.

 

	
(d)

	
No Manufacturing Rights.  Nothing in this Agreement shall be interpreted to grant to Distributor any right to manufacture or to contract for the manufacture of the

Page 5 of 30

Products or to contact or deal directly or indirectly with Medizone’s manufacturers of the Products.

 

	
(e)

	
Limitations on Offering.  Distributor may not sell or distribute the Products outside the Territory and shall not offer the Products for sale or delivery outside the Territory, without the express written consent signed by Medizone.  For resale purposes, Medizone shall supply the Products only to the Distributor for resale in the Territory.  Medizone will prohibit other distributors to which it sells the Products from making sales of the Products to Customers in the Territory.

 

	
(f)

	
No Franchise or Business Opportunity Agreement. The Parties to this Agreement are independent contractors and nothing in this Agreement shall be deemed or constructed as creating a joint venture, partnership, agency relationship, franchise or business opportunity between Medizone and Distributor. Neither Party, by virtue of this Agreement, will have any right, power or authority to act or create an obligation, express or implied, on behalf of the other Party. Each Party assumes responsibility for the actions of their personnel under this Agreement and will be solely responsible for their supervision, daily direction and control, wage rates, withholding income taxes, disability benefits, or the manner and means through which the work under this Agreement will be accomplished. Except as provided otherwise in this Agreement, Distributor has the sole discretion to determine Distributor’s methods of operation, Distributor’s accounting practices, the types and amounts of insurance Distributor carries, Distributor’s personnel practices, Distributor’s advertising and promotion, Distributor’s Customers, and Distributor’s service areas and methods. The relationship created hereby between the Parties is solely that of seller and distributor. If any provision of this Agreement is deemed to create a franchise relationship between the Parties, then the Parties shall negotiate in good faith to modify this Agreement so as to effect the Parties’ original intent as closely as possible in a mutually acceptable manner in order that the transactions contemplated hereby be consummated as a distribution agreement and not a franchise agreement.

 

	
3.

	
Terms of Agreement Prevail Over Distributor’s Purchase Order. This Agreement is expressly limited to the terms of this Agreement and the Purchase Order Transaction Terms contained in the applicable Purchase Order. All Purchase Orders placed with Medizone by Distributor shall be in writing, submitted by mail, courier or electronic transmission such as e-mail, and Medizone will give effect to applicable Purchase Orders with reasonable promptness, and under no circumstances in a longer average delivery time than the rest of the distributors or direct customers.  The terms of this Agreement prevail over any terms or conditions contained in any other documentation related to the subject matter of this Agreement and expressly exclude any of Distributor’s general terms and conditions contained in any Purchase Order or other document issued by Distributor.

 

	
4.

	
Proprietary Rights.

 

	
4.1

	
Ownership. Subject to the express rights and licenses granted by Medizone in this Agreement, Distributor acknowledges and agrees that:

 

	
(a)

	
any and all Medizone’s Intellectual Property Rights are the sole and exclusive property of Medizone or its licensors;

Page 6 of 30

	
(b)

	
Distributor shall not acquire any ownership interest in any of Medizone’s Intellectual Property Rights under this Agreement;

 

	
(c)

	
any goodwill derived from the use by Distributor of Medizone’s Intellectual Property Rights inures to the benefit of Medizone or its licensors, as the case may be;

 

	
(d)

	
if Distributor acquires any Intellectual Property Rights in or relating to any product (including any Product) purchased under this Agreement (including any rights in any Trademarks, derivative works or patent improvements relating thereto), by operation of law, or otherwise, these rights are deemed and are hereby irrevocably assigned to Medizone or its licensors, as the case may be, without further action by either Party; and

 

	
(e)

	
Distributor shall use Medizone’s Intellectual Property Rights solely for the purposes of performing its obligations under this Agreement and only in accordance with this Agreement and the instructions of Medizone.

 

	
4.2

	
Medizone Intellectual Property.  Distributor acknowledges and agrees that the Products, in their current form as of the date of this Agreement, are proprietary to Medizone and all related Intellectual Property rights will at all times remain in Medizone.  As between Distributor and Medizone, Medizone shall (i) own any Intellectual Property in modifications to the industrial design of the case element of the Products, whether made by or for Medizone; and (ii) own any Intellectual Property in modifications to any other element, features or technology of the Products made by or for Medizone in the course of developing the Products.

 

	
4.3

	
Trademark License Grant. This Agreement does not grant either Party the right to use the other Party’s or their Affiliates’ Trademarks except as set out under this Section 4.3. Subject to Medizone’s trademark policies, which may be amended from time to time in Medizone’s sole discretion, and the terms and conditions of this Agreement, Medizone hereby grants to Distributor a non-exclusive, non-transferable and non-sublicensable license to use Medizone’s Trademarks in the Territory during the Term and the Post-term Sale Period solely on or in connection with the Service Business or the promotion, advertising and resale of the Products in accordance with the terms and conditions of this Agreement. Distributor will promptly discontinue the display or use of any Trademark or change the manner in which a Trademark is displayed or used with regard to the Product when requested by Medizone. Other than the express licenses granted by this Agreement, Medizone grants no right or license to Distributor, by implication, estoppel or otherwise, to the Product or any Intellectual Property Rights of Medizone.

 

	
4.4

	
License to Translated Marketing Materials and Other Documentation. To the extent that Distributor translates or causes to be translated, any of Medizone’s marketing materials, user manuals or other documentation, Distributor hereby irrevocably assigns all copyrights in these translations to Medizone, subject to a non-exclusive, non-transferable and non-sublicensable license to Distributor, hereby granted by Medizone, to use the translations in the Territory during the Term and the Post-term Sale Period solely on or in connection with the

Page 7 of 30

promotion, advertising, resale or use of the Product permitted under this Agreement.

 

	
4.5

	
Use of the Name “AsepticSure®” By Distributor.  Distributor is authorized to refer to and advertise itself as an authorized distributor of the Products in the Territory. Any use of the name “AsepticSure®” or “Medizone” by Distributor in connection with its distribution and sale of the Product or advertising of the names “AsepticSure®” or “Medizone” is at the Distributor’s sole cost and expense. Distributor shall not use the names “AsepticSure®” or “Medizone” or any Trademark:

 

	
(a)

	
on, directly, or indirectly in connection with, any place of business or other facility that is not used for, or directly related to, the marketing of the Product, with the exception of Trademarks placed in the Products that are used to perform the Service Business;

 

	
(b)

	
on, or directly or indirectly in connection with, any place of business or other facility that is located outside the Territory;

 

	
(c)

	
on, or directly or indirectly in connection with, signs, letterheads, advertising or other promotional materials, or otherwise, in a manner that would indicate that Distributor has any place of business or other facility located outside the Territory that is used for or related to the sale of Product; or

 

	
(d)

	
in, or directly or indirectly as a part of, the trade, corporate or firm name or style of Distributor or of any division, subsidiary or affiliate thereof.

 

	
4.6

	
Pre-approval of Certain Published Material.  Notwithstanding the foregoing, Distributor shall submit to Medizone for prior approval any proposed publication, advertising or other printed material identifying itself as an authorized Product distributor in the Territory, including references to itself as an authorized Product distributor in the Territory in any telephone, internet or other directory listings; provided, however, this Section 4 does not apply to those materials that were provided and approved by Medizone for Distributor’s intended use.

 

	
4.7

	
Prohibited Acts. Distributor shall not:

 

	
(a)

	
take any action that may interfere with any of Medizone’s rights in or to Medizone’s Intellectual Property Rights, including Medizone’s ownership or exercise thereof;

 

	
(b)

	
challenge any right, title or interest of Medizone in or to Medizone’s Intellectual Property Rights;

 

	
(c)

	
make any claim or take any action adverse to Medizone’s ownership of Medizone’s Intellectual Property Rights;

 

	
(d)

	
register or apply for registrations, anywhere in the world, for Medizone’s Trademarks or any other Trademark that is similar to Medizone’s Trademarks or that incorporates Medizone’s Trademarks in whole or in confusingly similar part;

Page 8 of 30

	
(e)

	
use any mark, anywhere, that is confusingly similar to Medizone’s Trademarks;

 

	
(f)

	
engage in any action that tends to disparage, dilute the value of, or reflect negatively on the products purchased under this Agreement (including Product) or any Medizone Trademark;

 

	
(g)

	
misappropriate any of Medizone’s Trademarks for use as a domain name without prior written consent from Medizone;

 

	
(h)

	
alter, obscure or remove any of Medizone’s Trademarks or trademark or copyright notices or any other proprietary rights notices placed on the products purchased under this Agreement (including Product), marketing materials or other materials that Medizone may provide; and

 

	
(i)

	
subject to Section 4.5 and Section 4.6, place Medizone’s name or any of Medizone’s Trademarks:

 

	
(i)

	
on, or directly or indirectly in connection with, any place of business or other facility that is not used for, or directly related to, the marketing of the Product;

 

	
(ii)

	
on, or directly or indirectly in connection with, any place of business or other facility that is located outside the Territory;

 

	
(iii)

	
on, or directly or indirectly in connection with, signs, letterheads, advertising or other promotional materials, or otherwise, in a manner that would indicate that Distributor has any place of business or other facility located outside the Territory that is used for or related to the sale of the Product; or

 

	
(iv)

	
in, or directly or indirectly as part of, the trade, corporate or firm name or style of Distributor or any division, subsidiary or affiliate thereof.

 

	
4.8

	
Notices and Protection of Intellectual Property.  Distributor shall ensure that all Products sold by Distributor and all related quotations, specifications and descriptive literature, and all other materials carrying Medizone’s Trademarks, are marked with the appropriate trademark notices in accordance with Medizone’s instructions.  Distributor shall cooperate with respect to protection of Medizone’s Intellectual Property rights in the Products.

 

	
4.9

	
Third Party Infringements.  Each Party will promptly notify the other of any infringements by third parties of rights in the Products, the Trademarks, Patents or related materials that come to such Party’s attention. Medizone undertakes to exercise all legal actions it deems reasonably necessary to protect and defend the Products against any infringement by third parties of these rights, and may bring legal actions against them for infringement of its Intellectual Property Rights.  Distributor shall cooperate fully in any such actions, and in such event Medizone shall bear the expenses of the legal action (including costs incurred by Distributor in taking any legal actions at Medizone’s request), and shall be entitled to retain any and all sums recovered in the legal action.

Page 9 of 30

	
4.10

	
No Continuing Rights. On expiration or earlier termination of this Agreement, subject to Distributor’s rights under the Post-Term Sale Period, and Distributor’s rights under any Service Only Business Period (as defined in Section 18.6(c)):

 

	
(a)

	
Distributor’s rights under this Section 4 cease immediately; and

 

	
(b)

	
Distributor shall immediately cease all display, advertising, promotion and use of all of Medizone’s Trademarks and shall not thereafter use, advertise, promote or display any trademark, trade name or product designation or any part thereof that is similar to or confusing with Medizone’s Trademarks or with any trademark, trade name or product designation associated with Medizone or any Product.

 

 

 

 

 

Page 10 of 30

	
4.11

	
Anti-Bribery Compliance.  The Distributor shall:

 

	
(a)

	
comply with all applicable laws, statutes, regulations, and codes relating to anti-bribery and anti-corruption in the Territory (“Relevant Requirements”);

 

	
(b)

	
comply with Medizone’s anti-bribery, anti-corruption and ethics policies as Medizone or the relevant industry or regulatory body may update them from time to time (“Relevant Policies”);

 

	
(c)

	
have and shall maintain in place throughout the term of this Agreement its own policies and procedures to ensure compliance with the Relevant Requirements and the Relevant Policies, and will enforce them where appropriate;

 

	
(d)

	
promptly report to Medizone any request or demand for any undue or suspicious financial or other advantage of any kind received by the Distributor in connection with the performance of this Agreement;

 

	
(e)

	
immediately notify Medizone (in writing) if a public official in the Territory becomes an officer or employee of the Distributor or acquires a direct or indirect interest in the Distributor, and the Distributor warrants that it has no such public officials as direct or indirect owners, officers or employees at the date of this Agreement;

 

	
(f)

	
within three (3) months of the date of this Agreement, and annually thereafter, certify to Medizone in writing signed by an officer of the Distributor, compliance with this clause by the Distributor and all persons referred to under Section 4.11(e). The Distributor shall provide such supporting evidence of compliance as Medizone may reasonably request.

 

	
(g)

	
The Distributor shall ensure that all of its suppliers, agents, subcontractors and other members of its group or Affiliates who perform services or provide goods in connection with this Agreement do so only on the basis of a written contract which imposes on and secures from such persons terms equivalent to those imposed on the Distributor in this Section 4.11 (“Relevant Terms”). The Distributor shall be responsible for the observance and performance by such persons of the Relevant Terms, and shall be directly liable to Medizone for any breach by such persons of any of the Relevant Terms.

 

	
(h)

	
Breach of this Section 4.11 shall be deemed a material breach.

 

	
4.12

	
Covenant Not to Compete.  In consideration of the grant of exclusivity in the Territory under this Agreement, except for the exercise of Distributor’s rights under any Service Only Business Period, and unless the Agreement is terminated by Distributor pursuant to Section 18.5 of this Agreement, Distributor agrees that during the Term of this Agreement, and for a period of two (2) years thereafter (the “Restricted Period”), it will not compete with the business of Medizone by owning, lending to, operating or working as an employee, contractor, consultant, officer, director or agent for any person or entity engaged in the business of Medizone.  Likewise, neither Distributor nor any of its Affiliates shall perform

Page 11 of 30

activities of the type which in the ordinary course of business would involve the utilization of Confidential Information protected from disclosure by this Agreement.

 

	
4.13

	
Covenant of Non-Solicitation.  Distributor agrees that during the Restricted Period, and unless the Agreement is terminated by Distributor pursuant to Section 18.5 of this Agreement, neither it nor its Affiliates will directly or indirectly solicit or attempt to solicit any business in competition with the business of Medizone from any Customers with whom Distributor had contact at any time during its representation of Medizone pursuant to this Agreement.  Distributor further agrees that during the Restricted Period, it will not directly or indirectly solicit or attempt to solicit any vendors of Medizone with whom Distributor had contact at any time during the Term to provide services or products to any business which competes with the business of Medizone.

 

	
4.14

	
Covenant of Non-Recruitment. Distributor agrees that during the Restricted Period, it will not directly or indirectly solicit or attempt to solicit any employee of Medizone for the purpose of encouraging, enticing, or causing said employee to voluntarily terminate employment with Medizone.

 

	
4.15

	
Covenant of Price on Products. Medizone undertakes that the price of Products will not be higher than prices charged by Medizone to other Medizone distributors and best clients worldwide.  If at any time Medizone, or its successors or assigns in connection with any Change of Control Transaction (as defined in Section 28 below) ceases to sell Products to third party customers or distributors as part of their business operations, the price of Products to Distributor under this Agreement during the Term and any Post Term Sales Period will not be higher than two (2) times the direct cost of the Products to Medizone (or any of Medizone’s successors or assigns)(such direct costs to exclude, for example, any pro rata general overhead costs of Medizone).

 

	
4.16

	
Patent Registration.  Medizone represents that on July 5, 2012, it entered into the national phase in Brazil patent application (serial no. 112012000384-4), its primary health care patent application under the International Patent Protection Treaty (the “Primary Health Care Patent”), that the Primary Health Care Patent is deemed to have the international filing date of July 5, 2010 of Medizone’s original international patent application, and that examination of the application was timely requested in April 2013.  To date, no objections have been received by Medizone with respect to the Primary Health Care Patent from the Brazilian Patent Office.  Medizone agrees to use its reasonable best efforts to continue to process the pending Primary Health Care Patent in Brazil.  Distributor, it its discretion, shall have the right to cause Medizone to file and process a substantially similar health care patent application in other countries within the Territory, provided that (i) Distributor pays all fees, costs, and expenses associated with such application and prosecution, and (ii) Distributor shall not acquire any ownership interest in any such patent application funded by Distributor under this Section 4.16 or in any of Medizone’s Intellectual Property Rights under this Agreement.

Page 12 of 30

	
5.

	
Design and Engineering Changes.  Distributor may from time to time suggest engineering or technical changes to the Product; however, the ownership of and the right to implement any changes, including those suggested by Distributor, shall be the exclusive right of Medizone.  Product branding shall remain Medizone specific and Medizone shall have the final decision on all design, engineering and other matters regarding the Products.  Distributor acknowledges that the Products contain trade secrets of Medizone and its licensors, and, in order to protect such trade secrets, Distributor agrees not to disassemble, decompile or reverse engineer any software, firmware or hardware components of any Products, or permit any third party to do so.  Except as expressly authorized by this Agreement, Distributor will not: (i) copy or reproduce Products; (ii) modify Products; or (iii) alter, remove or obscure the Intellectual Property Rights notices of Medizone or its licensors that appear on the Products or Product packaging.

 

	
6.

	
Distributor’s Responsibilities.  Distributor shall, in good faith and at its own expense, have the following obligations and responsibilities under this Agreement:

 

	
(a)

	
use reasonable best efforts to promote, market, advertise and sell the Products to Customers located in the Territory consistent with good business practice and the specific sales goals targets mutually agreed upon for each calendar year. If there is no agreement on the sales goals, those stated in column 3 of the table in Annex A attached hereto will prevail.  Distributor shall use its best efforts to maximize the sales volume of the Products within the Territory.  If Distributor fails, in the aggregate, to achieve the sales goals mutually agreed upon (or if not agreed upon, fails to achieve, in the aggregate, at least sixty percent (60%) of the per country sales goals set forth in column 3 of the table in Annex A) in any particular Territory country during a period of four (4) consecutive years (i.e., after all sales of Distributor in that country are aggregated for the entire four-year period), then Medizone shall have the right (but not be obligated) to terminate Distributor’s exclusivity rights with respect to that particular Territory country, as provided in Section 2(b) of this Agreement and as further explained and described in Annex A attached hereto and by this reference incorporated herein.  However, in the event of a Change in Control Transaction, the rights of any successor in interest to Medizone to terminate Distributor’s exclusivity rights with respect to a particular country shall be governed by the alternative percentage of sales goals provided in Section 32(g).

 

	
(b)

	
establish and maintain a sales and marketing organization sufficient to develop according to the mutually developed business plan the market potential for the sale of the Products, independent sales representatives and a distribution organization and facilities sufficient to make the Products available for shipment by Distributor to each Customer immediately on receipt of order;

 

	
(c)

	
only resell or offer to resell the Products that Distributor currently has in inventory or that have been ordered from Medizone and which order has been accepted by Medizone as available for delivery to Distributor, unless Distributor has received prior written authorization from Medizone;

 

	
(d)

	
develop and execute a marketing plan sufficient to fulfill its obligations under this Agreement;

Page 13 of 30

	
(e)

	
have sufficient knowledge of the industry and products competitive with each Product (including specifications, features and benefits) so as to be able to explain in detail to the Customers:

 

	
(i)

	
the differences between the Products and competing products; and

 

	
(ii)

	
information on standard protocols and features of each Product;

 

	
(f)

	
observe all reasonable directions and instructions given to it by Medizone in relation to the marketing, advertisement and promotion of the Products, including Medizone’s sales, marketing and merchandising policies as they currently exist or as they may hereafter be changed by Medizone, to the extent that these marketing materials, advertisements or promotions refer to the Products or otherwise use Medizone’s Trademarks;

 

	
(g)

	
in any and all contact between Distributor and any Customer, the Distributor must identify to the Customer Distributor’s full legal name, trade name, or both;

 

	
(h)

	
market, advertise, promote and resell Products and conduct business in a manner that reflects favorably at all times on Products and the good name, goodwill and reputation of Medizone;

 

	
(i)

	
promptly Notify Medizone of and address and investigate any complaint or adverse claim about any Product or its use of which Distributor becomes aware; provided, that nothing in this Agreement requires Distributor to reveal proprietary pricing information; and

 

	
(j)

	
on the last Business Day of each month, provide Medizone with a written survey of the current and six-month forecast of demand for the Products in the Territory, especially in relation to similar or competing products.

 

	
7.

	
Authority to Perform Under this Agreement. Distributor shall, at its own expense, obtain and maintain required certifications, credentials, licenses and permits necessary to conduct business in accordance with this Agreement.

 

	
8.

	
Government Approval. Distributor shall comply with all applicable laws and regulations in the conduct of its business, including obtaining any necessary governmental licenses or approvals for distribution and sale of the Products within the Territory.  Distributor shall be responsible at its sole expense for and shall obtain and/or comply with all governmental laws and regulations applicable to the export, import and distribution of the Products in the Territory. If at any time during the Term or the Post-term Sale Period any notification, registration or approval is required for giving legal effect in any applicable jurisdiction to this Agreement or the transactions contemplated under this Agreement, Distributor shall:

 

	
(a)

	
immediately take whatever steps may be necessary to properly notify, register or obtain approval;

 

	
(b)

	
be responsible for any charges incurred in connection with notifying, registering or obtaining this approval; and

 

	
(c)

	
keep Medizone currently informed of its efforts regarding this Section 8.

Page 14 of 30

Medizone is not obligated to ship any Product or other materials to Distributor under this Agreement until Distributor has provided Medizone with satisfactory evidence that this approval, notification or registration is not required or that it has been obtained.

 

	
9.

	
Quality.  Distributor shall maintain the quality of customer service at a high level, consistent with Distributor’s practices for its other products.

 

	
10.

	
Prohibited Acts. Notwithstanding anything to the contrary in this Agreement, neither Distributor nor Distributor Personnel shall:

 

	
(a)

	
engage in any unfair, competitive, misleading or deceptive practices respecting Medizone, Medizone’s Trademarks or the Products, including any product disparagement or “bait-and-switch” practices;

 

	
(b)

	
separate any software or accessories sold, bundled or packaged with any Product from the Product or sell, license or distribute the software or accessories on a standalone basis, or remove, translate or modify the contents or documentation of or related to the software or accessories, including, without limitation, any end user license agreements or warranty statements;

 

	
(c)

	
market or distribute the Products other than in the form and packaging as delivered by Medizone to Distributor under this Agreement;

 

	
(d)

	
sell or offer to sell any of the Product outside the Territory without the prior written consent of Medizone (which consent may be withheld or withdrawn for any or no reason);

 

	
(e)

	
ship or otherwise deliver Product to any facility in a location that has not been approved by Medizone or is outside the Territory;

 

	
(f)

	
sell or offer to sell any Product or other Medizone-branded Product other than the Products purchased from Medizone or another distributor authorized by Medizone;

 

	
(g)

	
sell or show any NFR Products to any third party, except to demonstrate the NFR Products to one or more prospective Customers;

 

	
(h)

	
during the Term and the Post-term Sale Period, promote, market, sell or distribute Products using promotional information and material, unless the promotional information or material was provided by Medizone under the terms of this Agreement; or

 

	
(i)

	
during the Term or the Post-term Sale Period cease to function actively as a full-service distributor of products and services similar to the Products and services authorized under this Agreement.

 

	
11.

	
Recalls.  Medizone shall have the right at any time and at its own cost, to recall Products supplied by it to Distributor, whether such recall is demanded by any government agency or effected voluntary by Medizone.  Medizone shall give prompt notice to Distributor upon determining that any Products should be recalled.  Distributor shall cease and desist from making further shipments or use of the relevant Products supplied by Medizone until Medizone has resolved the issue.

Page 15 of 30

	
12.

	
Service and Support.  Distributor shall have responsibility for and shall provide, and/or ensure that third parties appointed by Distributor provide, reasonable customer and consumer support for Products sold by or through Distributor.  Medizone shall provide such engineering and technical support to Distributor and shall use commercially reasonable efforts to resolve customer or consumer concerns or inquiries relating to Medizone’s Products if Distributor cannot address such concerns or inquiries.

 

	
13.

	
Product Claims.  Distributor will be solely responsible for any representations or claims made by it regarding the Products, other than those contained in Medizone’s current promotional literature or documentation.

 

	
14.

	
Sales and Marketing.

 

	
(a)

	
Branding and Marketing Material.  Distributor and Medizone will collaborate on developing and mutually agree upon branding for the Product and for its packaging within the Territory.  The lead brand on the Product itself will be “AsepticSure®”.  The Trademarks shall appear on the Products, all Product packaging and all Product documentation as provided elsewhere in this Agreement.  Distributor shall, at its sole discretion and expense, create advertising, marketing and other sales material for the Product for use within the Territory, beyond that supplied by Medizone.  Distributor shall include the Trademarks in all marketing materials only as approved in writing by Medizone.

 

	
(b)

	
Development and Marketing Plans. On or before each Quarterly Business Review, Distributor shall provide to Medizone information it deems relevant to the marketing and public relations plans for the Products within the Territory.

 

	
15.

	
Project Management and Business Reviews.

 

	
(a)

	
Project Management.  Distributor and Medizone shall each designate one technical and one business contact as the primary individuals responsible for communications regarding development of the Product ready for go-to-market within the Territory.  The primary contacts shall conduct regular monthly progress meetings for the purposes of monitoring the program progress to schedule, industrial design, development, manufacturing, packaging and logistics.  Except as expressly provided in this Agreement, Medizone shall have final responsibility and decision-making authority on all matters related to the Product.

 

	
(b)

	
Quarterly Business Reviews.  The contacts of Distributor and Medizone identified under Section 15(a) above, shall meet at least quarterly to review the status of sales of the Product within the Territory, to agree upon minimum advertised pricing for the Products within the Territory, to discuss other issues related to this Agreement, and to review Distributor’s marketing plans and roadmap and identify opportunities for new products and/or enhancements to existing Products.  These and all other meetings required to be held under this Agreement may be held face-to-face, or by conference call or video conference or similar media.

 

	
16.

	
Pricing and Payment Terms.

 

	
(a)

	
Terms of the Sale. Medizone shall sell Products to Distributor at the Prices and on the terms and conditions set out in this Agreement, including the Exhibits and Schedules hereto.

Page 16 of 30

	
(b)

	
Payments and Reports.  Distributor shall make Payment for Products as provided in Exhibit A, by this reference incorporated in and made a part of this Agreement.  No Product will ship until Medizone as indicated on Exhibit A has received payment.

 

	
(c)

	
Product Pricing.  Distributor shall determine the price for the Products to be sold within the Territory in its sole discretion, giving consideration to the distributor resale prices identified on Exhibit A.  Pricing on Exhibit A is subject to change at the sole discretion of Medizone upon written notice not less than 60 days to Distributor.  However, no pricing change shall affect the price of any Product for which Medizone has accepted a purchase order prior to its notification to Distributor of such pricing change.

 

	
(d)

	
Costs.  Each Party shall bear its own costs associated with its business and activities under this Agreement.

 

	
(e)

	
Taxes.  Distributor shall be solely responsible for collection and/or payment of all sales, use, excise, value added and other taxes, governmental duties or assessments, arising out of this Agreement, other than taxes on Medizone’s income.

 

	
(f)

	
Inco Terms.  Products shall ship F.O.B. Medizone’s shipping facility in Kingston, Ontario, or from our manufacturing partner, Cogmediz, in Worcester, Massachusetts.  Title of goods shall transfer at F.O.B. point in Kingston or Worcester, as the case may be.

 

	
(g)

	
Availability/Changes in Product. Medizone may, in its sole discretion:

 

	
i.

	
remove Product from Exhibit A on fifteen (15) Business Days’ Notice to Distributor; and

 

	
ii.

	
add to the Product on Exhibit A on five (5) Business Days’ Notice to Distributor; and

 

	
iii.

	
without Notice to Distributor, effect changes to any Product or parts/accessories thereto (except where continued availability is required by Law),

 

in each case, without obligation to modify or change any Product previously delivered or to supply new Product meeting earlier specifications. For the avoidance of doubt, this provision does not expand the rights of Medizone to cancel shipment under a Purchase Order.

 

	
17.

	
Confidential Information.

	
17.1

	
Use and Disclosure.  The Receiving Party of Confidential Information shall not disclose to any person or use for any purpose, except as expressly permitted by this Agreement, any Confidential Information of the Disclosing Party.  The Receiving Party may disclose Confidential Information only to its employees and independent contractors who need to know such information, and who are required to keep such information confidential. The Receiving Party shall give the Disclosing Party’s Confidential Information at least the same level of protection

Page 17 of 30

as it gives its own Confidential Information of similar nature, but not less than a reasonable level of protection.  The Receiving Party shall maintain Confidential Information in a safe and secure place and shall not copy Confidential Information except to the extent necessary for the purposes of this Agreement.  Confidentiality obligations shall survive for so long as the Confidential Information is not made public.  It shall not be a violation of this Agreement if Confidential Information is required to be disclosed by law or judicial order, provided that prior written notice of such required disclosure is given to the Disclosing Party as soon as practicable in order to give the Disclosing Party the chance to object to the disclosure or to seek a protective order.

 

	
17.2

	
Injunctive Relief.  Each Party acknowledges that the other Party’s Confidential Information is highly valuable to the other Party, that any breach of its obligations under this Agreement with respect to confidentiality will severely damage the other Party, the extent of which damage would be difficult to ascertain and, therefore, that other Party shall be entitled to, among other remedies, immediate temporary and permanent injunctive relief (without bond) and other equitable relief for any such breach from a court or authority of competent jurisdiction.

 

	
18.

	
Term and Termination.

 

	
18.1

	
Term.  The initial term (“Initial Term”) of this Agreement begins on the Effective Date and shall terminate on 31 December 2019, subject to prior termination as provided below.

 

	
18.2

	
On expiration of the Initial Term (and each Renewal Term as defined below), this Agreement automatically renews for additional successive four-year terms unless and until (i) Distributor provides Notice of non-renewal at least 60 Business Days before the end of the then-current term, or (ii) Medizone provides Notice of non-renewal at least 60 Business Days before the end of the then-current term, provided Distributor has failed to achieve at least 60% of the mutually agreed upon sales goals for each calendar year as may be established by the Parties.  If there is no agreement on the sales goals, those stated in column 3 of the table in Annex A attached hereto will prevail.  However, in the event of a Change in Control Transaction, the rights of any successor in interest to Medizone to provide a Notice of non-renewal pursuant to this Section 18.2 shall be governed by the alternative percentage of sales goals provided in Section 32(g).  For purposes of this Section 18.2, calculations shall be based upon total sales by Distributor within the Territory during the immediately preceding 4-year Term, compared to the total sales Distributor would have achieved during the Term had it met its calendar year sales goals provided for in the mutually agreed-upon goals, or if none, the goals set forth in column 3 of the table in Annex A, or (iii) termination by the Parties as otherwise permitted under this Agreement or applicable Law (each a “Renewal Term” and together with the Initial Term, the “Term”). If the Term is renewed for any Renewal Term(s) pursuant to this Section 18.2, the terms and conditions of this Agreement during each such Renewal Term are the same as the terms in effect immediately before such renewal, subject to any change in Prices payable for the Product and payment terms during the applicable Renewal Term as determined by Medizone.

Page 18 of 30

	
18.3

	
In the event that Medizone issues such Notice, except for termination by Medizone under Section 18.4, Distributor may operate as a distributor in the Territory for twelve (12) months from the date of the Notice of non-renewal provided for in Section 18.2 (the “Post-term Sale Period”).  Without limiting the generality of the foregoing, during the Post-term Sale Period, Medizone will give effect to applicable Purchase Orders for Products and/or spare parts with reasonable promptness, and under no circumstances in a longer average delivery time than the rest of the distributors or direct customers.

 

	
18.4

	
Medizone’s Right to Terminate. Medizone may terminate this Agreement by providing Notice to Distributor:

 

	
(a)

	
if Distributor fails to pay any amount when due under this Agreement (“Payment Failure”) and the failure continues for 15 days after Distributor’s receipt of Notice of nonpayment;

 

	
(b)

	
if within any 12-month period, two (2) or more Payment Failures occur;

 

	
(c)

	
if Distributor breaches any provision of this Agreement (other than a Payment Failure), and either the breach cannot be cured or, if the breach can be cured, it is not cured by Distributor within 30 Business Days after Distributor’s receipt of Notice of such breach;

 

	
(d)

	
if Distributor becomes insolvent or files, or has filed against it, a petition for voluntary or involuntary bankruptcy or under any other insolvency Law, makes or seeks to make a general assignment for the benefit of its creditors or applies for, or consents to, the appointment of a trustee, receiver or custodian for a substantial part of its property, or is generally unable to pay its debts as they become due;

 

	
(e)

	
if Distributor fails to observe or perform any term, covenant or condition of Distributor’s under any agreement with Medizone, other than this Agreement, and the default continues beyond any grace period set out in the other agreement for the remedying of the default;

 

	
(f)

	
if Distributor distributes within the Territory, competing hospital disinfection equipment using a mixture of hydrogen peroxide (H2O2) and ozone (O3).

 

	
(g)

	
if Distributor:

 

	
i.

	
sells, leases, exchanges, transfers or disposes of a material portion of Distributor’s assets;

 

	
ii.

	
merges or consolidates with or into any other Person, unless the surviving entity has a net worth greater than or equal to its net worth immediately before the merger or consolidation; or

 

	
iii.

	
undergoes a Change of Control, in any case without Medizone’s prior written consent; or

 

	
(h)

	
in the event of a Force Majeure Event affecting Distributor’s performance under this Agreement for more than 30 consecutive days.

 

Any termination under this Section 18.4 is effective on Distributor’s receipt of Medizone’s Notice of termination or any later date set out in the Notice.

Page 19 of 30

 

		18.5	
Distributor’s Right to Terminate. Distributor may terminate this Agreement by providing Notice to Medizone:

 

		(a)	
if Medizone materially breaches any material provision of this Agreement and either the breach cannot be cured or, if the breach can be cured, it is not cured by Medizone within 15 Business Days after Medizone’s receipt of Notice of such breach;

 

		(b)	
if Medizone becomes insolvent or files, or has filed against it, a petition for voluntary or involuntary bankruptcy or under any other insolvency Law, makes or seeks to make a general assignment for the benefit of its creditors or applies for, or consents to, the appointment of a trustee, receiver or custodian for a substantial part of its property, or is generally unable to pay its debts as they become due; or

 

		(c)	
in the event of a Force Majeure Event affecting Medizone’s performance under this Agreement for more than 30 consecutive Business Days.

 

Any termination under this Section 18.5 is effective on Medizone’s receipt of Distributor’s Notice of termination or any later date set out in the Notice.

 

	
18.6

	
Effect of Termination.  Upon termination of this Agreement for cause, Distributor shall lose its sole and exclusive rights of distribution of the Products.  Upon termination, each Party shall return to the other Party or destroy and confirm to the other Party the destruction of all copies of the other Party’s Confidential Information, except that each Party may retain one copy of the other Party’s Confidential Information for archival purposes.  In addition to where it is so stated, it is agreed that Sections 4, 13.7, 16, 17, 18.6, 22, 29, 30, and 32 shall survive termination of this Agreement.  The Term’s expiration or earlier termination does not affect the following rights or obligations:

 

	
(a)

	
any rights or obligations that are to survive the expiration or earlier termination of this Agreement;

 

	
(b)

	
any rights or obligations that were incurred by the Parties before the expiration or earlier termination; provided that all indebtedness of Distributor to Medizone of any kind is immediately due and payable on the effective date of the Term’s expiration or earlier termination, without further notice to Distributor.

 

	
(c)

	
Distributor’s Right to Continue Service Only Business.  Upon termination of this Agreement, including the termination of Distributor’s distribution, exclusivity, and other rights as provided in Sections 2 and 4.3 through 4.5, Distributor shall retain the limited right to continue to own (not distribute) any Products previously purchased by Distributor and to continue to use such Products within the Territory only in its Service Business (as defined in Recital paragraph B).  Such rights by Distributor shall continue indefinitely (the “Service Only Business Period”) after termination of this Agreement, but shall be subject to Medizone’s rights to terminate the Service Only Business Period on the conditions set forth in Section 18.4

Page 20 of 30

(a) through (f) herein.  During the Service Only Business Period, Medizone shall continue to supply to Distributor such parts and supplies as may be reasonably necessary for Distributor to maintain Distributor’s previously-purchased Products in good working order.  The Parties understand and agree that during the Service Only Business Period, they shall continue to be subject to the terms of the following Sections of this Agreement, to the extent such terms reasonably pertain to Distributor’s performance of its Service Business:  Sections 4.1, 4.2, 4.7, 4.8, 4.11 through 4.14, 5, 7, 8, 10 through 13, 17, 22 through 28, 30, and 32.

 

	
18.7

	
Any Notice of termination under this Agreement automatically operates as a cancellation of any deliveries of Product to Distributor that are scheduled to be made after the effective date of termination, whether or not any orders for the Product had been accepted by Medizone. Regarding any Product that are still in transit on termination of this Agreement, Medizone may require, in its sole and absolute discretion, that all sales and deliveries of the Product be made on either a cash-only or certified check basis.

 

	
18.8

	
Subject to Section 18.6, on the expiration or earlier termination of this Agreement, Distributor shall promptly:

 

	
(a)

	
return to Medizone the NFR Products;

 

	
(b)

	
cease to represent itself as Medizone’s authorized distributor regarding the Product, and shall otherwise desist from all conduct or representations that might lead the public to believe that Distributor is authorized by Medizone to sell the Product;

 

	
(c)

	
return to Medizone or at Medizone’s request, destroy all documents and tangible materials (and any copies) containing, reflecting, incorporating or based on Medizone’s Confidential Information;

 

	
(d)

	
permanently erase all of Medizone’s Confidential Information from its computer systems, except for copies that are maintained as archive copies on its disaster recovery backup systems, its information technology backup systems or both. Distributor shall destroy any such copies on the normal expiration of its backup files; and

 

	
(e)

	
certify in writing to Medizone that it has complied with the requirements of this Section 18.8.

 

	
18.9

	
Subject to Section 18.5, the Party terminating this Agreement, or in the case of the expiration of this Agreement, each Party, shall not be liable to the other Party for any damage of any kind (whether direct or indirect) incurred by the other Party by reason of the expiration or earlier termination of this Agreement.

 

	
19.

	
Medizone’s Buy-back Right. Subject to Distributor’s rights under Section 18.3 regarding its rights to continue to act as a distributor and to service customer Products during any Post-Term Sale Period, within 30 Business Days following the Term’s expiration or earlier termination, Distributor shall Notify Medizone in writing of the quantity of all Products in Distributor’s remaining inventory. In the Notice, the Distributor shall separately identify which of those Product Distributor is then contractually obligated to

Page 21 of 30

sell to one or more Customers (“Committed Product”). On or before the 10th Business Day after Medizone receives the Notice, Medizone may, in its sole discretion, offer to purchase all or a portion of any remaining inventory (other than Committed Product) free of all liens, claims or encumbrances, at a price equal to the lesser of Distributor’s cost therefor and Medizone’s then-prevailing distributor price. Distributor must accept Medizone’s offer and promptly deliver, at Medizone’s expense and risk of loss, the ordered Product to Medizone’s designated carrier for delivery to Medizone. Repurchased Product must be returned in their original packaging, unopened and undamaged. Medizone shall pay the repurchase price to Distributor either by: (a) the issuance of a credit against any indebtedness of Distributor to Medizone; or (b) if the repurchase price exceeds the indebtedness, by payment of the excess to Distributor within 15 Business Days after delivery to Medizone.

 

	
20.

	
End of Term Purchase Restrictions. During the Term’s last three (3) months, Distributor shall purchase Product in quantities that are no greater than an amount that Distributor reasonably determines is necessary to meet Customer demand in that period.

 

	
21.

	
Representations, Warranties and Covenants of Distributor.  Distributor represents, warrants and covenants as follows:

 

	
22.1

	
Distributor has the right to enter into this Agreement and perform in accordance with the terms of this Agreement, and such actions do not violate any third party agreement or other obligation by which Distributor is bound.

 

	
22.2

	
it is duly qualified to do business and is in good standing in every jurisdiction in which such qualification is required for purposes of this Agreement, except where the failure to be so qualified, in the aggregate, would not reasonably be expected to adversely affect its ability to perform its obligations under this Agreement;

 

	
22.3

	
it has the full right, corporate power and authority to enter into this Agreement, to grant the rights and licenses granted under this Agreement and to perform its obligations under this Agreement;

 

	
22.4

	
the execution of this Agreement by its Representative whose signature is set out at the end hereof has been duly authorized by all necessary corporate action of Distributor; and

 

	
22.5

	
when executed and delivered by each of Medizone and Distributor, this Agreement will constitute the legal, valid and binding obligation of Distributor, enforceable against Distributor in accordance with its terms, except as may be limited by any applicable bankruptcy, insolvency, reorganization, moratorium, or similar laws and equitable principles related to or affecting creditors’ rights generally or the effect of general principles of equity.

 

	
22.

	
Limitations of Warranties.  EXCEPT AS OTHERWISE SPECIFICALLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATIONS OR WARRANTIES OF ANY KIND, WHETHER EXPRESS OR IMPLIED, WITH RESPECT TO ITS PRODUCTS, SERVICES, DOCUMENTS, OR OTHER MATERIALS, INCLUDING WITHOUT LIMITATION THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT AND FITNESS FOR A PARTICULAR PURPOSE.

Page 22 of 30

	
23.

	
Warranty Limitations.  Limited Warranties do not apply where the Product has been subjected to abuse, misuse, neglect, negligence, accident, improper testing, improper installation, improper storage, improper handling, abnormal physical stress, abnormal environmental conditions or use contrary to any instructions issued by Medizone; has been reconstructed, repaired or altered by Persons other than Medizone or its authorized Representative; or has been used with any Third Party Product, hardware or product that has not been previously approved in writing by Medizone.

 

	
24.

	
Extent of Liability. During the Warranty Period, regarding any Defective Product:

 

	
(a)

	
notwithstanding anything in this Agreement to the contrary, Medizone’s liability under any Limited Warranty is discharged, in Medizone’s sole discretion and at its expense, by:

 

	
(b)

	
repairing or replacing the Defective Product; or

 

	
(c)

	
crediting or refunding the Price of the Defective Product, less any applicable discounts, rebates or credits.

 

	
(d)

	
Distributor or Customer is responsible for all costs and risk of loss associated with the delivery of Defective Product to Medizone.

 

	
(e)

	
Medizone is responsible for all costs and risk of loss associated with the delivery of repaired or replaced Product to Distributor; and

 

	
(f)

	
Distributor is responsible for all costs and risk of loss associated with the delivery and return of the repaired or replaced Product to Customer.

 

	
(g)

	
All claims for breach of a Limited Warranty must be received by Medizone no later than five (5) Business Days after the expiration of the limited warranty period of the Product.

 

	
(h)

	
Distributor has no right to return for repair, replacement, credit or refund any Product except as set out in this Section 24. Distributor shall not reconstruct, repair, alter or replace any Product, in whole or in part, either itself or by or through any third party.

 

	
(i)

	
THIS SECTION 24 SETS FORTH DISTRIBUTOR’S SOLE REMEDY AND MEDIZONE’S ENTIRE LIABILITY FOR ANY BREACH OF ANY WARRANTY RELATING TO THE PRODUCT.

 

	
(j)

	
Except as explicitly authorized in this Agreement or in a separate written agreement with Medizone, Distributor shall not service, repair, modify, alter, replace, reverse engineer or otherwise change the Product it sells to Customers.

 

	
25.

	
Warranties Disclaimer; Non-reliance. EXCEPT FOR THE LIMITED EXPRESS WARRANTIES DESCRIBED IN SECTION 24, (A) NEITHER MEDIZONE NOR ANY PERSON ON MEDIZONE’S BEHALF HAS MADE OR MAKES ANY EXPRESS OR IMPLIED REPRESENTATION OR WARRANTY WHATSOEVER, INCLUDING ANY WARRANTIES OF: (i) MERCHANTABILITY; OR (ii) FITNESS FOR A PARTICULAR PURPOSE, WHETHER ARISING BY LAW, COURSE OF DEALING, COURSE OF PERFORMANCE, USAGE OF TRADE OR OTHERWISE, ALL OF WHICH ARE EXPRESSLY DISCLAIMED, AND (B) DISTRIBUTOR

Page 23 of 30

ACKNOWLEDGES THAT IT HAS NOT RELIED ON ANY REPRESENTATION OR WARRANTY MADE BY SELLER, OR ANY OTHER PERSON ON SELLER’S BEHALF, EXCEPT AS SPECIFICALLY DESCRIBED IN SECTION 24 OF THIS AGREEMENT.

 

	
26.

	
Third Party Products. Distributor acknowledges and agrees that Product purchased by Distributor under this Agreement may contain, be contained in, incorporated into, attached to or packaged together with the products manufactured by a third party (“Third Party Products”). Third Party Products are not covered by the Limited Warranty. For the avoidance of doubt, Medizone makes no representations or warranties regarding any Third Party Products.

 

	
27.

	
Right of First Refusal. At any time after this Agreement has been in effect for a minimum of three (3) years following the Effective Date (the “ROFR Period”), Distributor shall not, directly or indirectly through an Affiliate, enter into any agreement or consummate any transaction relating to the sale of all or substantially all of Distributor’s assets or a transaction or series of transactions resulting in a Change of Control of Distributor with any Person other than Medizone (a “Third-party Transaction”) except in compliance with the terms and conditions of this Section 27.

 

	
(a)

	
If, at any time during the ROFR Period, Distributor receives a bona fide written offer for a Third-party Transaction that Distributor desires to accept (each, a “Third-party Offer”), Distributor shall, immediately following receipt of the Third-party Offer, notify Medizone in writing (the “Offer Notice”) of the identity of all proposed parties to such Third-party Transaction and the material financial and other terms and conditions of such Third-party Offer (the “Material Terms”). Each Offer Notice constitutes an offer made by Distributor to enter into an agreement with Medizone on the same Material Terms of such Third-party Offer (the “ROFR Offer”).

 

	
(b)

	
At any time prior to the expiration of the 15-day period following Medizone’s receipt of the Offer Notice (the “Exercise Period”), Medizone may accept the ROFR Offer by delivery to Distributor of a written notice of acceptance/binding letter of intent containing the Material Terms and any standard and customary conditions applicable to a transaction of this nature, executed by Medizone; provided, however, that Medizone is not required to accept any non-financial terms or conditions contained in any Material Terms that cannot be fulfilled by Medizone as readily as by any other Person (e.g., an agreement conditioned upon the services of a particular individual or the supply of a product exclusively under the control of such third-party offeror).

 

	
(c)

	
If, by the expiration of the Exercise Period, Medizone has not accepted the ROFR Offer, and provided that Distributor has complied with all of the provisions of this Section 27, at any time following the expiration of the Exercise Period, Distributor may consummate the Third-party Transaction with the counterparty identified in the applicable Offer Notice, on Material Terms that are the same or more favorable to Distributor as the Material Terms set forth in the Offer Notice. If such Third-party Transaction is not consummated, the terms and conditions of this Section 27 will again apply and Distributor shall not enter into any Third-

Page 24 of 30

party Transaction during the ROFR Period without affording Medizone the right of first refusal on the terms and conditions of this Section 27.

 

	
(d)

	
For the avoidance of doubt, the terms and conditions of this Section 27 apply to each Third-party Offer received by Distributor during the ROFR Period.

 

	
28.

	
Sale of Medizone.  In the event of a sale of all or substantially all of the assets of Medizone, or the sale of a majority of the equity securities of Medizone (“Change of Control Transaction”), and consistent with the purpose and intent of the assignment provisions of Section 32(g) herein, Medizone agrees that in connection with and as a condition to the closing of any such Change of Control Transaction, subject to the provisos set forth in Section 32(g), Medizone shall secure the written agreement of any buyer or successor in any such Change of Control Transaction to abide by the terms of this Agreement that are applicable to Medizone herein.  Medizone also agrees to give Distributor written notice, within three (3) Business Days of Medizone and any third party executing any non-binding letter of intent or memorandum of understanding with respect to any such proposed Change of Control Transaction.

 

	
29.

	
Indemnification.

 

	
(a)

	
Each Party agrees to indemnify, defend and hold the other Party harmless from and against any and all claims, liabilities, judgments, costs, damages and expenses (including reasonable attorneys’ fees) arising out of (i) any breach of such Party’s obligations, warranties, covenants or representations in this Agreement; or (ii) any unrelated third party claim that such Party’s products or Intellectual Property infringes or misappropriates a third party’s Intellectual Property.

 

	
(b)

	
Indemnification Procedure.  With respect to any third party claims falling within the scope of this indemnification obligation, (i) each Party agrees to promptly notify the other of any claim or lawsuit for which it believes it is entitled to be indemnified; (b) the indemnifying Party shall assume, at its sole expense, the defense of such claim or lawsuit; (c) the Party being indemnified shall have the right to participate in the defense of any such claim or lawsuit with separate counsel, at its sole expense; and (d) the indemnified Party shall provide the indemnifying Party with the assistance, information and authority reasonably necessary to defend against the third party claim, at the indemnifying Party’s expense.

 

	
(c)

	
Infringement Cure.  If a material component of the Product is finally held or believed by the indemnifying Party to infringe or its distribution is enjoined, the indemnifying Party will use reasonable efforts to obtain a license or grant of rights under the rights that have been infringed, modify the Product so it is non-infringing or provide a substitute Product or component thereof that is non-infringing, or if the foregoing are not commercially reasonable or the indemnifying Party fails to so cure the problems, either Party may terminate the license and distribution rights for the infringing Product upon written notice to the other Party.  Neither Party shall be liable for infringement based on modification of the Product by any other Party (excluding such Party’s own agents), or the combination or use of the Product with any other product, equipment, or process

Page 25 of 30

not furnished by such Party, if use of the Product alone and in its unmodified form would not have been an infringement.

 

	
(d)

	
Limitation of Warranties.  THIS SECTION STATES THE PARTIES’ ENTIRE OBLIGATION WITH RESPECT TO ANY CLAIM FOR INFRINGEMENT OR MISAPPROPRIATION OF ANY THIRD PARTY INTELLECTUAL PROPERTY RIGHTS.

 

	
30.

	
Limitations of Damages.  IN NO EVENT SHALL MEDIZONE OR Distributor BE LIABLE FOR, AND EACH PARTY COVENANTS NOT TO BRING ANY CLAIM FOR, SPECIAL, CONSEQUENTIAL OR INDIRECT DAMAGES (INCLUDING EXEMPLARY OR PUNITIVE DAMAGES), WHETHER OR NOT SUCH DAMAGES WERE FORESEEABLE OR THE PARTY WAS SPECIFICALLY ADVISED CONCERNING THE POSSIBILITY OF SUCH DAMAGES.  THE FOREGOING LIMITATIONS SHALL NOT APPLY TO THE PARTIES’ INDEMNIFICATION OBLIGATIONS OR TO A PARTY’S BREACH OF CONFIDENTIALITY OBLIGATIONS OR INTENTIONAL MISCONDUCT.

 

	
31.

	
Point of Sale Reports.  Within 30 days after the end of each quarter, Distributor shall deliver to Medizone a written report setting forth, in reasonable detail, the total net Products sold by it in such month.  Such report shall include: 1) Name and address of Distributor’s end customer, 2) Invoice date, 3) Quantity of each product sold, 4) Medizone part number, 5) Unit price, and 6) Extended price.

 

	
32.

	
Miscellaneous.

 

	
(a)

	
Entire Agreement; Amendment. The complete and exclusive statement of the agreement between the Parties relating to this subject matter shall consist of this Agreement.  For example, any prior discussions or understandings are superseded by the terms of this Agreement.  This Agreement may not be amended except by a written document signed by an authorized representative of both Parties.

 

	
(b)

	
No Waiver.  The waiver by either Party of any default or breach of this Agreement, or any obligation hereunder, shall be ineffective unless in writing.  No failure to exercise any right or power under this Agreement or to insist on strict compliance by the other Party shall constitute a waiver of the right subsequently to exercise such right or power or to insist on strict compliance.

 

	
(c)

	
Choice of Law.  This Agreement shall be governed by and construed in accordance with the laws of the state of Nevada, U.S.A., including its implementation of the Uniform Commercial Code.  The prevailing Party shall be entitled to an award of its costs and reasonable attorneys’ fees in any such action.

 

	
(d)

	
Force Majeure.  Neither Party shall be liable for any failure or delay in performing hereunder, if such failure or delay is due to war, strike, government requirements, acts of nature, acts or omissions of carriers, or other cause(s) beyond its reasonable control (“Force Majeure”); provided, however, that if a Party’s performance of any material obligation is reasonably expected to be delayed more than three (3) months due to any such cause, the other Party may terminate this Agreement upon 30 days’ prior written notice.

Page 26 of 30

	
(e)

	
Severability.  If any provision of this Agreement is held to be invalid, illegal or unenforceable by a court or authority of competent jurisdiction, such provision shall be modified by such court or authority to the minimum extent necessary to make it valid, legal and enforceable.  If the provision cannot be so modified, it shall be severed and all other provisions of this Agreement shall remain in full force and effect. If a provision is held illegal, invalid or unenforceable, the Parties also agree to negotiate reasonably and in good faith to modify this Agreement with a new provision that approximates the intent and purpose of the original provision as closely as possible, without being illegal or unenforceable.

 

	
(f)

	
Notices.  All notices (“Notice”) between the Parties shall be in writing and shall be sent by certified or registered mail or commercial delivery service, with provisions for a receipt, or facsimile (confirmed in writing thereafter), to the following addresses, or such other address a Party may specify by written notice:

 

Distributor

GYD S.A.

Los Cactus 1558

Lo Barnechea

Santiago, Chile

Attention: Gerardo Guzman Hargous

Email: Gguzman@bioasepsiscorp.com

Medizone International, Inc.

4000 Bridgeway, Suite 401

Sausalito, California 94965

U.S.A.

Attention: Edwin G. Marshall, CEO

with a copy of legal notices (which shall not constitute notice hereunder) to:

Durham, Jones & Pinegar

111 East Broadway, Suite 900

Salt Lake City, UT  84111

Attention:  Kevin R. Pinegar

U.S.A.

Fontaine y Cia

E mail: ffontaine@fontaineycia.cl

Attention: Francisco Fontaine

 

	
(g)

	
Assignment; Binding Effect.  Distributor may not sublicense or assign its rights or delegate its duties or obligations under this Agreement without prior written consent of Medizone, which shall not be unreasonably withheld.  This Agreement is binding upon and inures to the benefit of the Parties and their respective successors, representatives and permitted assigns.  Notwithstanding anything in this Agreement, in the event of a Change of Control Transaction (as defined above) prior to the expiration or termination of this Agreement, the rights of

Page 27 of 30

Distributor hereunder shall continue and this Agreement shall continue to be binding upon the successor in interest or purchaser of Medizone; provided, that Distributor is in full compliance with all provisions of and is not in breach under this Agreement at the effective date of such sale, merger or transaction.  In the event of a Change of Control Transaction involving Medizone, the percentage of sales goals figure referenced in Sections 6(a) and 18.2 herein shall be reduced from 60% to 30%.

 

	
(h)

	
Independent Contractors; No Representations.  The Parties are independent contractors, and neither Party shall have any right or authority to make any representations or warranties on the other Party’s behalf, or to assume or create any obligations or responsibilities, express or implied, on behalf of the other Party, or to bind the other Party in any way.  Neither Party is an agent, employee or legal representative of the other Party.

 

	
(i)

	
No Agency, Franchise, Partnership or Other Relationship.  This Agreement shall not be construed to create an agency, employer/employee relationship, franchisor/franchisee relationship, joint venture relationship or partnership between the Parties.  The Parties expressly agree that no franchise or partnership laws are intended to or shall apply to this Agreement or to the relationship of the Parties.

 

	
(j)

	
Relationship of the Parties.  The relationship between the Parties shall not be a partnership, joint venture or a merger of their assets or their fiscal or other liabilities or undertakings.  Neither Party shall have the right to bind the other Party, except as expressly provided for herein.  This Agreement is exclusive.  This Agreement shall be deemed to prevent either Party from entering into an agreement or negotiation of similar kind or nature with third parties.  All persons employed by either Party in connection with the Services provided under this Agreement shall be considered employees or agents of such Party only, and shall in no way, either directly or indirectly, be considered employees or agents of the other Party.

 

	
(k)

	
Publicity / Press Releases.  Neither Party may issue a press release or refer to the other Party publicly without such Party’s prior consent, which may not be unreasonably withheld.  The foregoing excludes any disclosure required under applicable law or regulation, including Securities and Exchange Commission regulation, or by any governmental agency, in which case the Party required to make the press release or public disclosure shall use commercially reasonable efforts to obtain the approval of the other Party as to the form, nature and extent of the press release or public disclosure prior to issuing the press release or making the public disclosure.

 

	
(l)

	
Execution in Counterparts.  This Agreement may be executed in any number of counterparts, each of which shall be deemed an original (including facsimile copies), but all of which together shall constitute one and the same instrument.

 

	
(m)

	
Headings.  Section and subsection headings contained in this Agreement are inserted for convenience of reference only, shall not be deemed to be a part of this

Page 28 of 30

Agreement for any purpose, and shall not in any way define or affect the meaning, construction or scope of any of the provisions hereof.

 

	
(n)

	
Further Actions.  Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.

[Signatures are on the next page.]

 

 

 

 

 

Page 29 of 30

SIGNATURES:

 

  

	
Distributor

	 	
Medizone International, Inc.

	 
	 	 	 	 
	 	 	 	 
	
By:                                                                    

	 	
By:                                                                    

	 
	 	 	 	 
	
Name: Gerardo Guzman Hargous

	 	
Name: Edwin G. Marshall

	 
	
Title: General Manager

	 	
Title: Chief Executive Officer

	 
	 	 	 	 
	
Date:                                                                 

	 	
Date:                                                                 

	 

 

 

Page 30 of 30

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00263-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00263-of-00352.parquet"}]]